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Given the pathophysiology associated with the Human Immunodeficiency Virus (HIV) and 
the reported predilection for frontal circuitries and deep white matter, one might expect that 
executive dysfunction forms part of the neurocognitive profile of people living with HIV. 
However, such deficits have mainly been reported for adults living with HIV. Adolescence is 
a period where significant growth and refinement of executive functioning occurs and 
therefore specific research focused on HIV-positive adolescents is needed. Adolescence is 
also a developmental period where poor adherence to Antiretroviral Therapy (ART) persists 
despite marked increases in the national roll out of ART in South Africa, which has 
significantly decreased HIV-related morbidity and mortality rates. Poor adherence is not only 
a threat to the efficacy of ART but is also linked to the emergence of drug-resistant HIV 
strains and identified as a key contributor in the persistence of some cognitive impairments 
among people living with HIV. Studies show that executive dysfunction can undermine 
adherence to ART particularly in adolescents, whose frontal lobes are still developing. 
The first aim of this study was to compare the executive function profile of a group of 
HIV positive adolescents with that of a matched HIV negative control group. Using P. 
Anderson’s (2002) model, executive functions were considered along the four subdomains: 
attentional control, processing speed, cognitive flexibility and goal setting. A second aim of 
the study was to investigate the relationship between executive function and levels of 
adherence to ART amongst the HIV positive adolescents in the sample. 
This cross sectional, between-groups study used a comprehensive neuropsychology 
test battery which was sorted into composite domains to investigate differences in executive 
functioning between the two study groups of adolescents aged between 14 to 16 (n = 22 in 
each group) using t-tests. Correlation coefficients were further computed to establish 
association between adherence and executive functioning. Apart from processing speed (p = 
0.42, after the removal of outliers), there were no significant between-group differences in 
executive functioning outcomes that emerged between the HIV-positive and HIV-negative 
groups. The neuropsychological test scores for both groups were largely in the borderline 
range. Correlations between adherence and executive functioning outcomes did not yield any 
significant associations for each of the executive function domains.  
The lack of significant between-group differences may be explained by the mitigating 
effects of ART in the CNS in the HIV-positive group. However, consideration should be 
given to social factors as these may be important mediators of cognition and may therefore 




in the current study did not conclusively provide evidence for the role of executive functions 
in adherence, given the noted limitations, further studies with larger samples should confirm 
such outcomes.   
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Since the roll out of antiretroviral therapy (ART), the treatment for Human 
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), in 2005, 
South Africa has realized major turnarounds in the course of HIV/AIDS, including reduced 
HIV-related morbidity and mortality rates (Statistics South Africa, 2019). However, despite 
an increase in the roll out of ART, HIV/AIDS remains a key national public health concern in 
South Africa (Global AIDS monitoring, 2018). In keeping with the global target of 
eradicating HIV/AIDS by 2030, the South African government took critical policy decisions 
aimed at combating the HIV/AIDS pandemic; ensuring, for example, that ART is available at 
public health service points (Statistics South Africa, 2019). The decision to roll out ART 
within the public health sector has produced significant gains; evidenced mainly by extended 
life spans of people living with HIV, for all affected ages (Statistics South Africa, 2019). 
However, poor adherence to ART threatens to reverse these gains. Generally, inconsistencies 
in adherence to ART have been identified as one of the leading contributors to ART failure 
(Falagas, Zarkadoulia, Pliatsika, & Panos, 2008; Giacomet et al., 2003; Solomon & Halkitis, 
2008) and has been noted to be particularly problematic amongst adolescents. Commonly, it 
is during adolescence that individuals typically learn of their HIV-positive status (Smith & 
Wilkins, 2015; Wiener, Mellins, Marhefka, & Battles, 2007) and also the stage where the 
responsibility of taking ART transfers from primary caregivers to personal responsibility 
(Giacomet et al., 2003; Smith & Wilkins, 2015). 
Of note, poor adherence to ART in adolescents has been identified as a key 
contributing factor to the persistence of some forms of neurocognitive impairment (Cattie, 
Doyle, Weber, Grant, & Woods, 2012; Hermetet-Lindsay et al., 2017). Specifically, there is 
growing evidence in research of greater prevalence of executive function impairments in 
HIV-positive adolescents than previously acknowledged (Cattie et al., 2012; Clark et al., 
2017; Laughton et al., 2013). Executive function generally refers to goal directed behaviour 
(Diamond, 2013). Impairment in this domain commonly results in every day functional 
decline and research suggests that it can also contribute to poor adherence patterns to ART 
(Diamond, 2013; Wood, Shah, Steenhoff, & Rutstein, 2009). Studies further show that 
executive dysfunction can directly impact adherence to ART particularly in adolescents, 
where continued brain development, especially in the frontal lobes, takes place (Kim et al., 
2014; Laughton et al., 2013; Nichols et al., 2016).   
However, studies on executive functions and individuals with HIV are typically 




particularly from South Africa (Laughton et al., 2013; Nichols et al., 2016). Given the 
necessity of good adherence for optimal health among HIV-positive adolescents, and the role 
that executive functions might contribute in achieving that goal, investigations into executive 
functioning generally, and in relation to adherence within the adolescent population, is 






Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) 
HIV is the virus that causes AIDS and is classified as a lentivirus. Two types of HIV 
are commonly reported in literature, HIV-1 and HIV-2 (Nyamweya et al., 2013). HIV-1 is 
more prevalent worldwide with HIV-2 more endemic in West Africa and in some parts of 
India (Nyamweya et al., 2013). Besides genome and geographic differences, these HIV types 
also differ in rates of infectivity or rates of transmission, with HIV-1 having a comparatively 
higher rate of transmission than HIV-2 (Esbjörnsson et al., 2019; Nyamweya et al., 2013). 
Another key difference is that with HIV-2 immunodeficiency occurs at a much slower rate, 
however, the life expectancy of those with HIV-2 is shorter than those with HIV-1 
(Esbjörnsson et al., 2019; Nyamweya et al., 2013).  HIV-1 infection, which is more 
prominent in Southern Africa, can be categorized into four main groups: M, N, O, P. Most 
HIV infections worldwide derive from group M; within this group 12 subtypes/clades are 
identified (subtype A – L). In South Africa, specifically, HIV-1 clade C is the most prevalent 
HIV infection subtype (Jacobs et al., 2009; Joska et al., 2011; Santos & Soares, 2010).  
HIV epidemiology. By the end of 2018, approximately 37.9 million people 
worldwide were living with HIV (WHO, 2019). Additionally, in 2018 it was estimated that 
770 000 people died from HIV-related causes and that there were 1.7 million new infections 
(WHO, 2019). However, despite these high figures, recent global data on the incidence of 
HIV reflects improvements in trends overtime. For example, global annual AIDS-related 
deaths, have declined from 1.9 million in 2004 to 940 000 in 2017 (UNAIDS, 2018). Global 
estimates further showed a decline in new infections, from 3.4 to 1.8 million, from 1996 to 
2017, respectively (UNAIDS, 2018). Global reductions in AIDS-related mortality rates were 
mainly attributed to increases in the rollout of HIV/AIDS treatment services (UNAIDS, 
2018). However, even with these promising estimates, it is reported that 180 000 children 
globally were infected with HIV in 2017, and in the same year, only 50% of HIV-infected 
children under the age of 15 were receiving treatment (UNAIDS, 2018). Hence, there is still 
much work to be done among youth with HIV.  
 Notwithstanding recent downward global trends of several key HIV indices, Sub-
Saharan Africa (SSA) remains deeply affected by the HIV/AIDS pandemic. To illustrate, of 
the estimated 37.9 million people worldwide living with HIV in 2017, 19.6 million were from 
SSA, specifically, Eastern and Southern Africa (UNAIDS, 2018). It is reported that in 2017 




infections were from countries within SSA (UNAIDS, 2018). For example, in 2017 alone, 
800 000 people (650 000 - 1 000 000) were infected with HIV in SSA making this region a 
hotspot for the virus (UNAIDS, 2018). Consistent with global HIV/AIDS estimates, key 
HIV/AIDS indicators for the SSA also reflect a downward trend. For instance, AIDS-related 
deaths in SSA declined by 42% and estimates for new infections overtime show a 30% 
decline from 2010 to 2017 (UNAIDS, 2018). The regional reduction in AIDS-related 
mortality rates was mainly attributed to an increased rollout of HIV/AIDS treatment services 
(UNAIDS, 2018).  
In South Africa, a regional analysis in 2017 revealed that the country was among 
those with the highest incidence of HIV in Sub-Saharan Africa (UNAIDS, 2018). Further, the 
national HIV prevalence rate in 2018 stood at 13.1% (Statistics South Africa, 2018). 
According to UNAIDS (2018) in 2017 in South Africa, 280 000 children below the age of 
fourteen were living with HIV. Also consistent with global and regional trends, South 
Africa’s national HIV-related mortality rates also appear to be steadily declining over time. 
Specifically, the number of AIDS-related deaths has decreased steadily over time from 267 
417 in 2007 to 126 805 in 2019. Again, the observed decline in AIDS-related deaths was 
attributed to wider access to ART from increased and wider provincial roll out of ART 
especially within the public health sector (Statistics South Africa, 2019). 
HIV transmission. Children commonly contract HIV vertically (i.e., from mother to 
child, either in-utero, during birth or through breastfeeding (Hoare et al., 2016). Hence, a 
number of adolescents have lived with HIV since birth. However, the introduction of ARV 
treatment to pregnant mothers has resulted in a marked decline in prenatal transmission of 
HIV (Smith & Wilkins, 2015).  Other transmission modes of HIV infection, commonly 
reported among adolescents, are more behavioural, i.e., through sexual contact, blood 
transfusions and use of contaminated drug instruments (Nagarajan et al., 2012).  
HIV pathophysiology. HIV enters the central nervous system (CNS) relatively early 
in the disease process by crossing the blood brain barrier (BBB) (Chiriboga, Fleishman, 
Champion, Gaye-Robinson, & Abrams, 2005; Kumar et al., 2009; McArthur, Brew, & Nath, 
2005).  The BBB is a protective layer of endothelial cells surrounding the CNS separating it 
from the rest of the body (Abbott, Rönnbäck, & Hansson, 2006). The BBB is highly selective 
in what it allows into the brain and excludes potentially harmful substances to the brain 
(Abbot et al., 2006). Amongst its functions, the BBB is responsible for regulating the 
environment within the brain, ensuring that the environment is conducive for optimum 




protective barrier, the HI virus is able to penetrate it and manages to cross into the CNS 
within weeks of infection through infected monocytes, macrophages, and lymphocytes, 
which are able to cross the BBB unimpeded (Abbot et al., 2006; Chiriboga et al., 2005; 
Koekkoek, de Sonneville, Wolfs, Licht, & Geelen, 2008; Llorente et al., 2014; McArthur et 
al., 2005; Tan & McArthur, 2012; Van Rie, Harrington, Dow, & Robertson, 2007). 
Once in the brain HIV replicates itself and triggers extensive neurotoxic effects and 
acute inflammatory processes which activate the production of cytokines, which are proteins 
that assist in the regulation of immune cells to sites of infection (Smith & Wilkins, 2015; 
WHO, 2019). The secondary inflammatory and neurotoxic processes incite massive depletion 
of CD4 cells, which are responsible for fighting infections in the body; these processes 
further promote damage to synaptic-dendritic networks and ultimately bring about 
widespread destruction of neurons (Sarma et al., 2014; Smith & Wilkins, 2015; Tan & 
McArthur, 2012;  Thomas, Greenfield, Talavera, & Roos, 2016; Van Rie, Harrington, Dow, 
& Robertson, 2007). The chronic inflammatory and neurotoxicity processes are also 
implicated in added weakening of the BBB, which fosters further entry of the HI virus into 
the CNS. Eventually, due to prolonged activation, the immune system becomes compromised 
to the point of being effectively defenceless against opportunistic diseases (Nyamweya et al., 
2013; Smith & Wilkins, 2015; WHO, 2019).  
Key brain regions affected by HIV. Although HIV has widespread impact on the 
brain and is generally known to be regionally nonspecific (Chiriboga et al., 2005, Mitchell, 
2006), some studies suggest that damage to the basal ganglia is the hallmark of HIV, and that 
this neuroanatomical structure is especially vulnerable to HIV infection (Laughton et al., 
2013; McArthur et al., 2005; Woods, Moore, Weber, & Grant, 2009). Other brain regions that 
are particularly vulnerable to HIV include the brain stem, the frontal cortex and deep white 
matter (Abbott et al., 2006; Laughton et al., 2013; Smith & Wilkins, 2015; Thomas et al., 
2016). Woods et al. (2009) also note that HIV has a predilection for the fronto-striatal 
pathways; however, this apparent predilection may be mediated by damage to the basal 
ganglia. Combined evidence from neuroimaging studies of both infected adolescents and 
adults further point out that HIV affects the anatomical structure and function of white matter 
tracts and numerous neural networks and various brain regions including temporal, parietal 
cortices and the brain stem (P. Anderson, 2002; McArthur et al., 2005; Sarma et al., 2014). 
The suggestion that HIV is partial to frontal cortices including frontal circuitries and deep 
white matter may well explain the presentation of EF deficits seen in HIV-positive 




the frontal regions of the brain, Spies et al. (2016) reports that an HIV diagnosis particularly 
in childhood is linked to morphological and functional alterations in the frontal brain regions, 
which are associated with poor neuropsychological outcomes.  
For example, a study by Sarma et al. (2014), using magnetic resonance imaging 
(MRI) to compare the brain scans of prenatally-infected adolescents on ART (N = 16) (one 
adolescent contracted HIV through a blood transfusion before age 1) and aged-matched 
Controls (N = 14), found marked differences in white matter and grey matter volumes 
between the two groups. Essentially, the study found bilateral white matter atrophy 
predominantly in the corpus callosum and external capsule and grey matter hypertrophy in 
various brain areas (including frontal, occipital and temporal gyri) in the brain images of the 
HIV-positive group relative to the controls. The authors attributed the white matter loss to 
HIV-related neural injury and death caused by axonal disconnections. The study further 
observed grey matter volume increase in the HIV- positive adolescents’ brain scans. The 
authors noted that this was an unexpected finding and postulated that the grey matter increase 
was likely attributable to HIV-related chronic inflammation in the brain as well as probable 
toxicity from ART, both which may have resulted in swelling of neurons.  
Another study by Cohen et al. (2015) of 35 HIV-positive adolescents and 37 HIV-
negative controls aged 8 - 18 years also found significant differences in white matter and grey 
matter volumes. Even though the sample was virologically suppressed and generally 
clinically asymptomatic (28 of the HIV-positive group were on ART), the study noted lower 
brain volumes for the HIV-positive group. In this instance, the white and grey matter in the 
HIV-positive group was smaller in comparison to the controls. The study findings further 
noted diffuse white matter hyper-intensities in the HIV-positive group suggestive of ongoing 
immune activation and specifically indicative of gliosis, myelin loss or vascular injury.  
Collectively, the findings of the above-mentioned studies highlight potential changes 
in brain morphology from HIV infection, as well as the likely long-term effects of HIV, even 
in the context of ART treatment in some studies. Given these brain morphological changes, 
there exists vast literature on the neurocognitive disorders associated with HIV infection.  
Neurocognitive disorders among individuals living with HIV. HIV is associated 
with moderate to severe neurocognitive impairments, even in the context of increased access 
to HIV treatment (Donald et al., 2015; Van Rie et al., 2007). These impairments are 
commonly referred to as HIV associated neurocognitive disorders (HAND) (Heaton et al., 




HIV associated neurocognitive disorders (HAND). Researchers have reported that an 
estimated 30-60% of HIV-positive individuals have some degree of HAND (Cattie et al., 
2012; Cross, Combrinck, & Joska, 2013; Wagner at al., 2016). HAND generally affects 
several cognitive domains (Woods et al., 2009). The taxonomy of HAND includes 
Asymptomatic neurocognitive impairment (ANI), Mild neurocognitive disorder (MND) and 
HIV- associated dementia (HAD) (Antinori, Heaton, & Marder, 2007; McArthur et al., 2005; 
Woods et al., 2009).  
 Asymptomatic neurocognitive impairment (ANI).  A diagnosis of ANI requires 
neurocognitive impairment in at least two domains without, however, interference in 
activities of daily living (ADLs). There should also be no delirium or signs of dementia. 
Mild neurocognitive disorder (MND). HIV-associated MND is similarly characterized 
by impairment in two or more neurocognitive domains, however there is mild interference in 
ADLs in this classification. Neurocognitive impairment in this classification should not meet 
criteria for dementia or delirium. 
HIV associated dementia (HAD). HAD encompasses moderate to severe 
neurocognitive impairment typically in multiple domains with marked interference in ADLs.  
 Based on their recent research on HIV-positive adolescents, with the recognition that 
the distinction between the different categories can be marginal, Hoare et al. (2016) proposed 
a revised taxonomy of HAND, in which the main point of departure is the inclusion of 
functional competence when determining the degree of impairment. In this taxonomy, HIV-
positive adolescents were classified along four types: no impairment, asymptomatic 
neurocognitive impairment, minor neurocognitive impairment and major neurocognitive 
impairment. A diagnosis for major neurocognitive impairment is given when the score on the 
Child Behaviour Checklist (CBCL) is <35, over and above impairment in two cognitive 
domains (Hoare et al., 2016). 
HIV encephalopathy (HIVE). HIVE is the most severe form of HAND and is 
considered to be one of the most common CNS neurologic presentations of HIV infection in 
children and adolescents (Donald et al., 2015). HIVE refers to generalized brain disease and 
damage associated with HIV (Donald et al., 2015; Mitchell, 2006). Brain scans of individuals 
with HIVE show diffuse cortical atrophy and widespread symmetrical deep white matter 
lesions (MacArthur et al., 2005). Fortunately, the introduction of HIV treatment (ART) has 
curbed the incidence of HIVE (McArthur et al., 2005).  
Neuropsychological Presentation of HIV. As noted, HAND generally affects a 




HIV-positive adolescents is therefore broad and generally includes deficits in general 
intellectual functioning, learning, attention, information processing speed, motor abilities, 
episodic memory, visual spatial ability and executive function (Fellows et al., 2014; Heaton 
et al., 2011; Heaton et al., 2015; Koekkoek et al., 2008; Nichols et al., 2016; Ruel et al., 2012; 
Woods et al., 2009). However, this study focusses primarily on general intellectual 
functioning and executive function, discussed below.  
General intellectual functioning. Significant disparities have been noted in 
intellectual functioning between HIV-positive adolescents and controls, with HIV-positive 
adolescents obtaining lower IQ scores than their control counterparts (Cohen et al., 2015; 
Koekkoek et al., 2008). Additionally, HIV-positive adolescents are more inclined to present 
with memory and learning difficulties when compared to samples of matched HIV-negative 
adolescents, which may impact on general intellectual functioning (Nichols et al., 2016; 
Wood, Shah, Steenhoff, & Rutstein, 2009). A study by Cohen et al. (2015) of HIV-positive 
adolescents (n = 35) and HIV-negative controls (n = 37) established that the HIV-positive 
cohort performed comparatively poorly on tests of IQ than the controls. Similarly, a study by 
(Hoare et al. (2016), which assessed a sample of South African children and adolescents (age 
6 -16), found that comparatively, HIV-positive children and adolescents (n = 86) performed 
more poorly than HIV-negative matched controls (n = 34) on verbal and performance IQ 
subtests.  
 Executive functions (EF). Executive function is a multifaceted neuropsychological 
construct that entails a diverse range of mental processes which include planning, decision 
making, self-regulation, processing information, inhibition of inappropriate behaviours, 
problem solving and sequencing and monitoring behaviour (Diamond, 2013; Nichols et al., 
2016; Nyongesa et al., 2019; Wood, Shah, Steenhoff, & Rutstein, 2009). For this reason, 
executive functions impact several aspects of living such as academic performance, 
psychological development, general social interaction and vocational prospects (Diamond, 
2013). Given the multifactorial nature of executive function it is not surprising that they have 
an overarching reach over quality of life and that such deficits are more likely to impair the 
capacity to undertake everyday tasks effectively and can degenerate to general functional 
decline.  
Given that executive functions are broad and multifactorial in nature, evaluating them 
through the rubric of a model is helpful; in this study I used P. Anderson’s executive function 




Executive function model. P. Anderson  (2002) proposes a model that provides an 
insightful framework into understanding the construct of executive functioning. His model 
postulates that executive functions can be separated into four discrete domains - namely 
attentional control, information processing, cognitive flexibility and goal setting. In keeping 
with similar notions on executive functioning, P. Anderson (2002) acknowledges that these 
domains though discrete, operate in an integrated manner and influence each other. The 


















Figure 1. P. Anderson (2002) executive function model 
 
Domain 1: Attentional control. Attentional control encompasses the ability to 
selectively direct one’s attention to specific information in spite of competing stimuli and 
distractions. This domain encapsulates one’s ability to inhibit automatized or instinctual 
responses. Attentional control further represents the ability to sustain one’s attention for an 
extended period of time, as well as the ability to regulate and monitor responses necessary for 
the execution of plans (P. Anderson, 2002). It follows, then, that attentional control is critical 
in adhering to procedure, error monitoring, and achievement of goals. It is also not surprising 
that individuals with attentional control impairments may exhibit lack of self-control, be 



























 Domain 2: Information processing. Information processing comprises fluency, 
efficiency and promptness at which input information is produced (P. Anderson, 2002). 
Fluent output in this regard is denoted by efficiency in which speech is generated. In general, 
information processing integrity is judged by the promptness, volume and quality of the 
information released.  
 Domain 3: Cognitive flexibility. Cognitive flexibility encompasses the ability to 
switch between different tasks and activities and adapt behaviour and responses to changing 
stimuli and changes in rules (P. Anderson, 2002).  A key component of cognitive flexibility is 
working memory which denotes the ability to consciously process information in short term 
memory (P. Anderson, 2002; Diamond, 2013). Cognitive flexibility further encompasses 
feedback utilisation which refers to the ability to evaluate and gain insight from mistakes; and 
conceptual transfer which refers to the ability to reconceptualise and formulate new 
strategies, attend and process different portals of information simultaneously (P. Anderson, 
2002).  
 Domain 4: Goal setting. Goal setting is defined as the ability to be creative and 
generate new concepts and strategies, and plan the steps necessary to execute these strategies 
in an efficient and organized manner (P. Anderson, 2002). A key component of goal setting is 
planning which underlies many aspects of everyday living. Planning encompasses the 
capacity to select choices among alternatives, organize and appropriately sequence behaviour 
towards accomplishing a specific goal (Cattie et al., 2012). Another feature of the goal setting 
domain is conceptual reasoning which speaks to the capacity to abstract central themes from 
stimuli that may be presented as outwardly discrete and unrelated (P. Anderson, 2002).  
Executive dysfunction associated with HIV. Given that executive functioning 
underlies much of everyday living, impairment in this domain is associated with significant 
deficits (Diamond, 2013). I also use P. Anderson’s (2002) executive function model to 
discuss some of the prominent deficits associated with an HIV diagnosis. 
  Attentional control. Research shows that an HIV diagnosis often produces difficulties 
in attentional control (Nichols et al., 2016). For example, a study by Koekkoek et al. (2008) 
of 22 adolescents aged between 6 and 17 who had contracted HIV perinatally reported that 
the HIV-positive adolescents performed poorly on a task that assessed attentional control, 
relative to controls. This study found that the HIV-positive adolescents were not only slower 
than the controls, but that they made more errors than what was considered age appropriate, 
which may reflect poor error monitoring. Poor error monitoring is commonly associated with 




Information processing speed. Information processing deficits generally depict a 
slowness that pervades mental output. This slowness is usually clinically illustrated by 
hesitancy of output and overall reduction in output production (P. Anderson, 2002).  A study 
by Koekkoek et al. (2008) of a sample of HIV-positive adolescents observed markedly 
reduced information processing speed in the performance of the adolescents. Similar findings 
were reported by Nagarajan et al. (2012), with significantly poorer processing speed reported 
for the sample of 16 HIV-positive adolescents than for the 14 matched HIV-negative 
controls. Likewise, a South African study found information processing deficits in a sample 
of HIV-positive adolescents (n = 30) when contrasted with an HIV-negative matched sample 
of adolescents (n = 69).  Consistent with previous research, the study attributed its finding to 
HIV’s predilection for the frontostriatal circuitry, which plays a significant role in the ability 
to process information (Fraser, 2014). 
Cognitive Flexibility. HIV- related deficits in cognitive flexibility include failure to 
adapt to new expectations, being rigid and inflexible in thought, preferring rituals and 
procedure because of an inability to adapt to change. Individuals who are impaired in this 
domain commonly engage in perseverative conduct and tend to repeat mistakes (P. Anderson, 
2002). For example a study by Cohen et al. (2015) on a sample of HIV-positive adolescents 
(n = 35) (between 8 and 18 years) with healthy controls (n = 37) matched for age, sex and 
SES found that the HIV-positive adolescents struggled with cognitive flexibility mainly due 
to poorer working memory when compared to their healthy controls (n = 37).  
Furthermore, a study by Nichols et al. (2016) reported that adolescents (between 9 
and 19 years) who had contracted HIV prenatally, performed more poorly on a switching 
task, relative to controls, which may be indicative of difficulties with shifting between tasks, 
which is a component of cognitive flexibility (P. Anderson, 2002). The controls in this study 
were, however, adolescents that were prenatally exposed to HIV, but uninfected, which 
literature notes are not ideal controls as they too present with cognitive deficits (Jankiewicz et 
al., 2017; Nichols et al., 2016). 
Goal setting. Impairment in this domain commonly presents in the form of poor 
problem solving and planning, poor reasoning, disorganised behaviour and a dependence on 
previous strategies despite an awareness of risks associated with them (P. Anderson, 2002). 
Fujiwara, Tomlinson, Purdon, Gill, and Power (2015) report on impairment in decision 
making of HIV-positive individuals (n = 20) compared to matched HIV-negative controls (n 
= 20). The study results showed that the HIV-positive individuals exhibited reduced planning 




finding was attributed to impairment in the ability to plan ahead and a reduced ability to pre-
empt risk. Although the study was focused on adults, the findings are informative given that 
adolescents are widely documented in literature to be impulsive and inclined to engage in 
risky behaviour even outside the context of an HIV diagnosis (Laughton et al., 2013).  
Executive functions and socioeconomic status (SES). Besides the neuropathological 
effects of HIV and resultant neuropsychological sequelae, given that people living with HIV 
are overrepresented in low SES communities, such environmental effects also need to be 
considered, especially with outcome domains like executive functions, which are so closely 
tied to everyday behaviour (Hackman et al., 2015; Noble et al., 2015). Evidence from 
literature suggests that adolescents present differently, cognitively, depending on their 
socioeconomic backgrounds (Hackman, Gallop, Evans, & Farah, 2015; Noble et al., 2015). 
Generally, low SES is associated with poor executive functioning particularly in the domains 
of working memory, attentional control, inhibition, mental flexibility and planning (Hackman 
et al., 2015).  Additional evidence from brain scans reveal brain structural differences 
according to SES (Noble et al., 2015). These structural differences appear in diffuse brain 
regions including frontal, cingulate and temporal cortices in which language and executive 
functions were noted to be negatively affected (Noble et al., 2015). Hence, individuals with 
HIV may experience a double hazard, in terms of the direct effects of HIV together with 
possible environmental effects (Hackman et al., 2015; Noble et al., 2015; Lawson & Farah, 
2017).  
Adolescence 
Adolescence, which according to WHO is the developmental stage from age 10 – 19 
(WHO, 2018), is widely regarded as the period where significant growth and refinement of 
executive functioning occurs (Dumontheil, 2015; Laughton et al., 2013; Romer, Reyna, & 
Satterthwaite, 2017). Affect regulation, which is also a component of executive function, is 
also noted to improve significantly during this stage (Romer, Reyna, & Satterthwaite, 2017). 
The changes in cognition and affect that occur in adolescence are sub-served by structural 
changes particularly in the forebrain and temporal cortices which result in marked 
improvements in mental abilities (Steinberg, 2005). 
Adolescent behavioural instability. Despite a general marked improvement in 
mental abilities at adolescence, there is also evidence of impulsivity and increased HIV risky 
behaviour during this stage (Romer et al., 2017). This is because adolescents by and large 
find novel experiences enticing. The attraction to novelty pervades many aspects of 




(Cattie et al., 2012; Reisner et al., 2009; Romer et al., 2017). In the context of HIV, 
adolescent risky behaviours commonly include unprotected sex and substance abuse, which 
add to the risk of contracting HIV (Cattie et al., 2012; Nichols et al., 2015; Smith & Wilkins, 
2015; Steinberg, 2005). Literature explains that adolescent behaviour is mostly driven by the 
expectation of a reward, which suggests that adolescents are likely to engage in risky 
behaviour even while aware of the negative consequences associated with that particular 
behaviour (Dumontheil, 2015). Romer et al. (2017) adds that adolescents are sensation 
seekers mainly due to heightened dopaminergic activation at this developmental stage. So 
compelling is the pull towards sensation fulfilment that adolescents tend to disregard caution 
and frequently engage in risky behaviour.   
Brain development in adolescence. During adolescence the brain undergoes 
significant brain maturation mainly through the processes of myelination and pruning which 
is associated with growth and refinement of cognitive ability (Laughton et al., 2013). During 
adolescence these brain maturation processes are especially pronounced in the prefrontal 
cortex which is the brain region that is widely regarded as the executive centre for cognition 
(Romer et al., 2017; Steinberg, 2005). 
Myelination is a process that is carried out by oligodendrocytes which produce 
myelin, a sheath that covers axons and is responsible for regulating axonal transmission by 
especially ensuring rapid transmission. Myelination of frontal regions commences soon after 
birth and spans into adolescence and young adulthood and is generally associated with the 
maturation of key cognitive functions such as processing speed and problem solving (V. A. 
Anderson et al., 2001; Laughton et al., 2013; Zillmer, Spiers, & Culbertson, 2008).  
Pruning essentially refers to the elimination of mostly weak and generally redundant 
neurons and poorly connected synaptic connections which leads to a more sculpted brain and 
thus increased efficiency in neuronal connectivity (Romer et al., 2017). Pruning is thought to 
reach maximal level at adolescence and to occur much more preferentially in the pre-frontal 
brain region resulting in grey matter decline in this brain region (Romer et al., 2917). It is 
widely postulated in literature that pruning of neurons at adolescence is largely experience 
driven which means that it is significantly influenced by experiences that adolescents 
encounter at this stage. Pruning, like myelination is associated with an improvement in 
cognitive functions such as abstraction and improved decision making (Noble et al., 2015; 





HIV Treatment  
The introduction of Highly Active Antiretroviral Therapy (HAART) substantially 
changed the trajectory and outcomes of HIV by markedly reducing morbidity and mortality 
rates related to the virus (Giacomet et al., 2003; Heaton et al., 2011; Nachega, Mills, & 
Schechter, 2010; Spies, Ahmed-Leitao, Fennema-Notestine, Cherner, & Seedat, 2016; 
Willen, Cuadra, Arheart, Post, & Govind, 2017; Williams et al., 2006). HAART constitutes 
the prescription of a combination of drugs from at least two drug categories (for example, 
nonnucleoside reverse transcriptase inhibitors (NNRTI), integrase inhibitors, protease 
inhibitors (PI)) in the treatment of HIV (Koekkoek, de Sonneville, Wolfs, Licht, & Geelen, 
2008; Smith & Wilkins, 2015; Tan & McArthur, 2012). Earlier trials of treatment for children 
and adolescents used a mono-therapeutic ARV approach, which produced significant clinical 
improvements noted in both neurologic and neurodevelopmental domains (Chiriboga et al., 
2005). However, the use of single-drug therapies eventually had to be scaled down after the 
onset of drug-resistant HIV strains. These drug-resistant HIV strains severely weakened 
treatment impact and necessitated a review of treatment protocols (Chiriboga et al., 2005, 
Smith & Wilkins, 2015). The introduction of combination therapy thus arose from the need to 
find an efficacious treatment protocol adequately potent to restrain the mutation of drug-
resistant HIV strains (Chiriboga et al., 2005). The distinguishing feature of combination 
therapy is that, unlike single therapies, this mode of treatment attacks the virus at different 
points of the replication cycle. For this reason, combination drug therapy has significantly 
reduced disease progression and HIV-related deaths in children and adolescents (Chiriboga et 
al., 2005; Smith & Wilkins, 2015).   
Currently, HAART is the primary treatment approach to HIV infection in adults, 
adolescents and children. HAART significantly reduces viral replication, improves the 
integrity of the immune system, and prevents mutations of drug-resistant strains (Chiriboga et 
al., 2005, Smith & Wilkins, 2015). HAART has also markedly reduced AIDS-related deaths 
in children and adolescents – with a reported 70% reduction in HIV-positive children since its 
roll-out (Chesney, 2000; Chiriboga et al., 2005; Mitchell, 2006; Rivera, Frye, Steele, 2014).  
Another widely recognised benefit of HAART is its remarkable success rate in reducing 
opportunistic infections, which were the main cause for high mortality rates among children 
pre-HAART (Rivera et al., 2014). Since combination therapy not only reduces mortality and 
morbidity in children and adolescents but also helps to preserve the immune system, it has 




development for HIV-positive children and adolescents (Rivera et al., 2014; Smith & 
Wilkins, 2015).  
Adherence to ART.To maintain the positive health outcomes arising from ART, 
adherence rates of 90-95% are recommended (Hudelson & Cluver, 2015; Nachega et al., 
2014; Peltzer & Pengpid, 2013; Reisner et al., 2009). High adherence is considered to be a 
reliable predictor for viral suppression, slowed disease progression and overall increase in life 
expectancy (Nachega et al., 2010; Saberi, Mayer, Vittinghoff, & Naar-King, 2014). 
Conversely, poor adherence rates are linked to increased viral loads and mutations of drug-
resistant HIV strains which can ultimately result in treatment failure (Hudelson & Cluver, 
2015; Malee et al., 2009; Nachega et al., 2004; Nichols et al., 2016; Waldrop-Valverde et al., 
2010). Poor adherence rates may also increase the likelihood of transmission from an 
unsuppressed viral load (Kim et al., 2014). Unfortunately, poor adherence patterns persist, 
particularly among adolescents and threaten to unravel the vast benefits of ART (Kim et al., 
2014; Laughton et al., 2013; Nichols et al., 2016).   
Factors that impact on adolescent adherence to ART.  Literature cites different 
factors for poor adherence among adolescents. These consist of physical factors which 
include HIV-related motor disability and side effects from ART which often deter optimal 
adherence (Malee et al., 2008; Nichols et al., 2012; Smith & Wilkins, 2015). Psychosocial 
factors such as stigma are additionally noted to impact negatively on adherence patterns 
among adolescents; notably, psychosocial and physical factors often intersect (Chan et al., 
2015; Simbayi et al., 2007; Williams, 2014). However, of these factors, cognitive factors, 
specifically executive dysfunction, appears to be often implicated as a key contributing factor 
to adolescents’ poor adherence patterns.  
Executive dysfunction and adherence. An inverse relationship between adherence to 
ART and executive dysfunction is often portrayed in literature; where greater executive 
function impairment is associated with poorer adherence to ART (Waldrop-Valverde, Jones, 
Gould, Kumar, & Ownby, 2010). This is because executive functions are essential in 
managing often rigorous medical treatment plans and in keeping up with regular 
appointments to health facilities (Cattie et al., 2012; Nichols et al., 2016; Waldrop-Valverde 
et al., 2010). Specifically, literature suggests that adolescents with HIV tend to struggle with 
processing information related to their medication and also with planning for their medication 
due to executive dysfunction (Fraser, 2014; Laughton et al., 2015; Nichols et al., 2016). 




when processing speed is compromised the ability to adequately process and understand 
complex medication stipulations becomes compromised (Barclay et al., 2010; Laughton et 
al., 2015; Nichols et al., 2016). Secondly, when mental processes are slowed, difficulties in 
absorbing new information such as dosage changes, which are common in ART, may present 
thus affecting adherence negatively (Barclay et al., 2010; Laughton et al., 2015; Nichols et 
al., 2016). Another prominent executive dysfunction characteristic that HIV-positive 
adolescents are often faced with is difficulties in goal setting especially planning.  
Establishing goals and planning the required steps to meet these goals is often an area HIV-
positive adolescents struggle with. Planning difficulties in HIV-positive adolescents often 
present as a failure to efficiently incorporate medication uptake into their daily schedules. 
Invariably, these planning difficulties are thought to manifest as lowered adherence patterns 
(Cattie et al., 2012; Laughton et al., 2015; Nichols et al., 2016).  
Measurement of Adherence. Diverse methods of measuring adherence are reported in 
literature and these broadly fall into three categories (Reisner et al., 2009).  
Subjective measurement method. This type of measurement includes the use of self-
reports, collateral reports from others e.g., caregivers. Although this method is widely used in 
research on ART adherence patterns, its major drawback is that it is highly reliant on 
cognitive competency, which is often compromised in HIV-positive individuals; and also, 
this method is susceptible to social desirability bias (Gaifer & Boulassel; Reisner et al., 
2009). However, this method is useful when exploring or investigating barriers to non-
adherence (Gaifer & Boulassel, 2019). 
Pharmacologic measurement method.  This type of measurement includes pill count, 
medical records of refills and the use of computerised monitoring systems of pill usage e.g., 
insertion of microchips in pill containers (Gaifer & Boulassel, 2019). A key advantage of this 
method is that its effectiveness is not dependent on the cognitive abilities of patients which 
may eliminate a degree of subjectivity. This method is also a useful predictor for HIV 
virologic failure in that with this method it is easier to determine if a rise in viral load stems 
from poor compliance patterns or ART failure (Gaifer & Boulassel, 2019).  
Physiological measurement method. This method includes measurements of plasma 
viral load levels, CD4+ count and ancillary laboratory analysis reports (Hermetet-Lindsay, 
2017). Viral load as a marker for adherence has been used widely in research, the outcomes 
of which suggest that it is a good indicator of the efficacy of ART (Hermetet-Lindsay, 2017, 
Margot et al., 2018, Nichols et al., 2016; Shoko & Chikobvu, 2019). This method is also 




(Shoko & Chikobvu, 2019). However, the standard threshold at which viral load suppression 
is achieved, which would suggest good adherence, varies according to the assays or 
laboratories used to assess plasma specimens. Generally, though, undetectable plasma 
readings of viral load are those ≤ 20 copies/ml or in some cases ≤ 50 copies/ml (Hermetet-
Lindsay, 2017, Margot et al., 2018, Shoko & Chikobvu, 2019; Williams, 2006). Despite its 
advantages, this method is however costly (Shoko & Chikobvu, 2019). 
Summary and Conclusion 
HIV typically enters the brain soon after infection and once in the brain HIV 
replicates itself resulting in a weakened immune system (Smith & Wilkins, 2015; WHO, 
2019). However, overtime, major milestones have been achieved in relation to treating and 
managing HIV infection such that HIV is now considered a manageable chronic disease 
(WHO, 2019). Of these milestones, the introduction of ART has had a major impact on 
efforts aimed towards combatting HIV/AIDS through mainly reducing HIV-related morbidity 
and mortality rates (UNAIDS, 2018; WHO, 2019). Adherence is however key in gaining 
maximum impact of ART. Besides physical and psychosocial challenges, frequently reported 
in the literature, emerging literature also seems to suggest that executive dysfunction may 
undermine optimal adherence to ART.  
Despite adolescents being at a heightened risk for HIV infection and exhibiting 
marked deficits in HIV-related executive function as well as higher rates of non-adherence, 
there is a general dearth of research that focusses on this population (Laughton et al., 2013). 
Moreover, there is even less attention given in research on potential associations between 
executive functioning and adherence patterns within this population specifically.  Frequently, 
research on executive functions in the context of HIV tends to focus on adults (Laughton et 
al., 2013; Waldrop-Valverde et al., 2010). The tendency to review mainly adult data on 
executive function provides a limited characterisation of HIV- related executive function 
across developmental stages mainly because HIV-positive adults and adolescents are at 
different stages of brain development and therefore adolescents are likely to present uniquely 
(Hinkin et al., 2004).  
Furthermore, existing literature that has explored HIV-related executive dysfunction 
has tended to measure single domains of this broad neuropsychological construct (e.g., 
working memory, problem solving) (Phillips et al., 2016). The limitation in relying on a 
single domain is that it does not effectively capture the broad nature of executive function. 
Viewing executive function through the lens of a multi-domain or composite approach as the 




into HIV-related executive dysfunction in adolescents (Phillips et al., 2018). Such a 
comprehensive insight into the profile of executive function deficits in the context of HIV as 
offered by this study can be helpful for future interventions. Additionally, despite the high 
rates of non-adherence observed in adolescents generally, to my knowledge, there is no 
research that has focussed on determining possible correlation between the domains of 
executive function according to P. Anderson’s (2002) executive function model and 
adherence.  
The current study therefore presents a more nuanced executive function composite 
approach to assessing executive function and adherence in HIV-positive adolescents and 
matched HIV-negative controls for a better understanding of the impact of HIV on executive 
functions in adolescents and the possible association with adherence.  
Aims and Hypothesis 
The aim of this study was to compare the executive function profile of a group of 
HIV-positive adolescents with that of a matched HIV-negative control group. Using P. 
Anderson’s (2002) model of executive function, executive functions were considered along 
the four subdomains: attentional control, processing speed, cognitive flexibility and goal 
setting. 
A second aim of the study was to investigate the relationship between executive 
function and levels of adherence to ART amongst the HIV-positive individuals in the sample. 
 Hypotheses.  The first study hypothesis was that the sample of HIV-positive 
adolescents would perform more poorly on executive function tests relative to the HIV-
negative control adolescents. A second hypothesis was that for the HIV-positive group, 








Research Design and Setting 
The current study was part of a larger study run by the Desmond Tutu HIV 
Foundation, HlangananiPlus Health Care Transition (HCT) whose main goal was to support 
HIV-positive adolescents to transition successfully to adult health care.  
The current study is a quantitative, cross sectional, between-groups study, with two 
groups (Field, 2009). The first group includes a sample of HIV-positive adolescents while the 
second group was a community recruited matched HIV-negative control group. Data 
collection for the study was carried out at the Hannan Crusaid Clinic at Gugulethu for the 
HIV-positive group and at the University of Cape Town (UCT) for the control group. 
Participants  
Recruitment. Participants for the HIV-positive group were recruited from the 
HlangananiPlus HCT study sample, while participants in the control group were recruited 
from communities surrounding or in close proximity to, Gugulethu (e.g., Khayelitsha, 
Nyanga). The recruitment of control participants was through word of mouth, personal 
contacts, UCT staff members, and some of the participants were asked whether they had 
friends and relatives who met the study criteria, and if so, to ask such friends or relatives 
whether they were interested in participating in the study.  
Sample. There were 44 participants (n = 22 per group) in the study sample aged 14 - 
16 years. All participants were isiXhosa first language speakers and were from a low SES 
background. To ensure homogeneity within the sample, the control participants were matched 
to the HIV-positive participants on age, home language and SES.  
Inclusion criteria. Participants had to meet specific requirements for inclusion into 
each group.  
HIV- positive group. Participants in the HIV-positive group had to be part of the 
HlangananiPlus HCT project run by the Desmond Tutu HIV Foundation. The HIV diagnoses 
of these participants had to be determined by a health practitioner. Related to this, 
participants in the HIV- positive group were to receive both general medical care and their 
HIV medication from the Hannan Crusaid clinic in Gugulethu.  
Control group. The control group included HIV-negative adolescents that had no 
reported developmental delays or neurological diagnoses that would compromise their CNS 
performance.   




HIV-positive group. Participants in the HIV-positive group were excluded if they 
were taking secondary HIV co-morbid medication such as medication for TB or meningitis. 
The basis for excluding these participants is that taking these medications may compromise 
adherence to ART because of risk of interaction between the medications and ART 
(Onyebujoh, Ribeiro & Whalen, 2007). Collateral information acquired by the Desmond Tutu 
study team from the medical files of participants was used to determine whether there were 
prescriptions for HIV co-morbid medication.    
Additionally, participants who were prenatally exposed to substance use (drugs and 
alcohol) were excluded. The reason for this exclusion criterion is that a diagnosis or condition 
that is associated with drug or alcohol usage during pregnancy such as Foetal Alcohol 
Spectrum Disorder (FASD) may confound existing HIV-related impairment. Generally, 
prenatal exposure to these substances is linked to developmental delays and CNS impairment 
(Mattson, Crocker, & Nguyen, 2011). Since the HIV-positive sample was drawn from the 
HlangananiPlus HCT larger study, this exclusion criteria was mainly determined through 
self-report in the larger study during recruitment. Parents were asked about their pregnancy 
with specific probing around whether their children were exposed to alcohol or drugs 
prenatally.  
Control group. The main exclusion criterion for the control group was an HIV 
diagnosis. To ensure that this study criterion was upheld; a Paediatric Neuropsychology 
Developmental Questionnaire short form version was completed by all the parents or 
caregivers of the control participants (See appendix A). In instances where it was not possible 
to physically distribute the questionnaire to parents and caregivers, the questionnaire was 
administered telephonically to determine eligibility.   
A second criterion was prenatal exposure to substance use (drugs or alcohol). As 
previously mentioned, exposure to these substances is commonly associated with 
developmental delays and CNS impairment (Mattson, Crocker, & Nguyen, 2011).   
Measures and Apparatus  
A demographic questionnaire was distributed for parents and caregivers to assess the 
SES of participants. However due to poor return of the questionnaire, the assessment measure 
of SES was replaced with school quintile.  
A battery of neuropsychological tests was administered to assess different domains of 
executive function. These measures included subtests from the Wechsler Abbreviated Scale 




(Wechsler, 2004); The Children’s Memory Scale (Cohen, 1997); Children’s Colour Trails 
Test (Llorente et al., 2009); Delis Kaplan Executive Function (Delis, Kaplan & Kramer, 
2001); NEPSY II (Korkman, Kirk & Kemp, 2007). A full description of these measures is 
provided next. I also indicate which tests correspond to the executive function domains 
included in P. Anderson’s (2002) model in Table 1 below. 
Table 1 
 Anderson’s executive function model 
Domain Tests Cognitive construct  
 Cognitive Flexibility: 
 
Numbers backwards (CMS) 
Switching (NEPSY-II) 
Verbal fluency condition 3 (DKEFS) 
Verbal fluency switching accuracy 
(DKEFS) 














Matrix reasoning (WASI) 







Information Processing: Coding (WISC) 
Symbol search (WISC) 














Note. Domains taken from P. Anderson (2002) model for executive function 
 
Wechsler Abbreviated Scale of Intelligence (WASI). The WASI was used to assess 
general intellectual functioning. The WASI was developed to assess general intellectual 
functioning in individuals from ages 6 to 89, and has four subtests: Vocabulary, Similarities, 
Block design and Matrix reasoning. All 4 subtests were utilised to obtain the Full Scale 
Intelligence Quotient (FSIQ). I also calculated the verbal IQ (VIQ) for each participant which 




(PIQ) which is a measurement of both Block design and Matrix reasoning. Given the 
association between intellectual ability and executive function (Brydges, Reid, Fox, & 
Anderson, 2012), the measurement of IQ was undertaken to exclude and control for the  
possibility of delays in general intellectual functioning.  
The Vocabulary subtest has 42-items and it is used to assess language development 
and vocabulary acquisition. For the initial four items, participants are required to give the 
names of pictures presented to them. For the rest of the items, the examiner reads out aloud 
words to individuals for which they are required to provide definitions.   
The Similarities subtest is a 26-item subtest that assesses verbal concept formation 
and reasoning. For the initial four items, participants are presented with a page with two rows 
of pictures. The participant has to identify which picture in the bottom row is thematically 
related to the pictures in the top row. For the rest of the items, the participant is presented 
with two words and is required to explain how they are similar. 
Block Design is a 13-item subtest that measures perceptual organization, spatial 
visualization, visual-motor coordination, and the capacity to conceptually perceive the 
abstract. Participants are presented with three-dimensional cubes with red and white patterns 
on the sides. They are shown different geometric designs which they are required to replicate 
using the cubes within a given time.  
Matrix reasoning is a 35-item subtest that assesses nonverbal reasoning. In this test 
participants are required to view and then select a possible missing piece from five options in 
order to complete a series of incomplete matrices.  
Psychometric properties. The content validity of the WASI was established when 
comparing similar items of subtests to corresponding subtests of other Wechsler batteries 
such as the WISC-III. The Vocabulary, Block design and Similarities subtests which are in 
both the WASI and the WISC-III demonstrate significant correlations of 0.72, 0.87, and 0.69 
respectively. The reliability coefficients between items in the Similarities subtest ranges 
between 0.81 and 0.91. The FSIQ, PIQ and VIQ correlation coefficients for both batteries are 
0.87, 0.76 and 0.82 respectively. Therefore, it can be assumed that the IQ scales and subtests 
of the WASI and WISC-III measure similar constructs (Wechsler, 1999). Additionally, the 
Vocabulary and Similarities subtests as well as the Matrix Reasoning subtests all demonstrate 
significant correlations of between 0.55 and 0.85 and 0.36 to 0.70 respectively.  
The WASI has been successfully used in several published studies conducted on 




Wechsler Intelligence scale for children – Fourth edition (WISC-IV). The WISC-
IV is a measure of general intelligence and has been normed and standardized for children 
and adolescents aged 6 to 16 years. It has ten core and five supplementary subtests and is 
focussed on testing four main domains, namely, verbal comprehension, perceptual reasoning, 
working memory and processing speed. For the current study I used the Coding and Symbol 
Search subtests to assess processing speed, which forms part of the information processing 
domain of P. Anderson’s (2002) model of executive function.  
In the Coding subtest participants are expected to copy symbols within numbered 
geometric boxes (numbered from 1- 9). The participant is expected to draw or insert each 
symbol corresponding to a specific box number within a given time limit of 120 seconds.  
In the Symbol Search subtest participants are presented with a target group of two 
symbols and a search group of five symbols. Participants are asked to indicate whether the 
target symbols match with any of five symbols in a search group by ticking on either a yes or 
no box. Participants are given 120 seconds to carry out this task. 
Psychometric properties. The internal reliability for the subtests of the WISC-IV 
ranges from 0.79 to 0.90, while the reliability coefficients of the composite scale ranges 
between 0.88 and 0.97. The test re-test reliability for the individual subtests ranges from 0.73 
to 0.97 and for the composite scales it ranges between 0.86 and 0.93.  
The WISC-IV has been successfully used in South African HIV research on paediatric 
samples (Hoare et al., 2016). 
A developmental neurocognitive assessment (NEPSY –II). The NEPSY-II is a 
battery of 32 subtests designed to assess neurocognitive functionality. The subtests are 
designed to cover six domains: Language, executive function and attention, visuospatial 
processing, memory and learning, and social perception. The NEPSY-II has been normed and 
standardised for children and adolescents aged 5 to 16 years (Korkman, Kirk & Kemp, 2007). 
I used the Inhibition and Switching subtests from the NEPSY-II.  The Inhibition subtest 
corresponds with the attentional control domain, while the Switching subtest forms part of the 
cognitive flexibility domain in P. Anderson’s (2002) EF model.   
The Inhibition subtest is used to assess the ability to inhibit automatic responses. The 
Inhibition test has three conditions or sub-components – Naming, Inhibition and Switching. I 
used the Inhibition and Switching sub-components for the present study. In the Inhibition 
condition, participants are asked to give alternate names to the shapes being presented to 
them. For example, in the stimulus sheet which has squares and circles, participants are 




see a circle. The same principle is applied to the directionality of arrows - participants are 
expected to say the opposite directions for the stimulus sheet showing arrows, for example 
participants are expected to say “down” for an arrow facing upwards and to say “up” for an 
arrow facing downwards. Participants are given a time limit of 240 seconds to complete this 
task. Underlying this ability is attentional control which is one of the domains in P. 
Anderson’s (2002) model for EF. 
The Switching subtest is used to evaluate an individual’s ability to switch between 
response types. For example, when they are presented with black circles, they are required to 
name the shape as they see it (e.g., say “circle” or “square” as they see it). However, when 
they see a white shape regardless of what shape it is, they are required to say the other 
shape’s name (i.e., if it’s a white square they are required to respond “circle”). Besides the 
use of shapes – circles and squares; the same switching principles are applied to arrows (up 
and down only). When the arrow is black participants are expected to say the correct 
direction however when it is white they are expected to say the opposite direction. The 
Switching condition has a time limit of 240 seconds. Impairment of this function is suggestive 
of difficulty with cognitive flexibility which forms part of P. Anderson’s (2002) model of EF.  
Psychometric properties. The NEPSY-II has a strong content and construct validity 
and established stability across different age groups with stability coefficients that range from 
0.62 to 0.89.  
The NEPSY has been widely used in South African paediatric research and 
specifically used as a measure of executive functioning in South African paediatric HIV 
research (Hoare et al., 2016; Phillips et al., 2016). 
Children’s Colour Trails Test (CCTT). The CCTT is designed to measure 
sequencing, flexibility and switching and is normed and standardized for children aged 8 to 
16 years (Williams et al., 1995). The CCTT consists of two components (CCTT 1 and CCTT 
2). The first component is a sequencing task in which participants are asked to connect 
numbers by drawing lines between a sequence of numbers distributed around a stimulus sheet 
(i.e., from 1 to 2, 2 to 3 etc.). Even though both trials were administered, for the current study 
analyses I only used the findings of the second trial of the CCTT (CCTT 2) whereby 
participants are presented again with a stimulus sheet with numbers displayed. However, 
unlike in the first component this time the same number is shown twice on the stimulus sheet 
in two different colours (yellow and pink). The participant is expected to sequentially join the 
numbers while alternating the colours (i.e., pink 1 to yellow 2, yellow 2 to pink 3, etc.), and is 




ability to switch between responses. The ability to switch between the different colours while 
keeping to the correct number sequencing is a measurement of cognitive flexibility which is 
one of the executive function domains outlined in P. Anderson’s (2002) model.  
 Psychometric properties. The reliability and validity of the CCTT 1 and CCTT 2 was 
examined using a sample of 54 children aged between 6–12-years with ADHD. At 8 and16 
week time points results showed a test retest reliability coefficient range of 0.46 - 0.68.   To 
establish factorial validity children with traumatic brain injury (TBI), other types of trauma 
and healthy controls were assessed. This analysis revealed a 3-factor loading structure; the 
first factor was categorized as perceptual tracking speed and ease of distractibility, an 
inability to control impulses and poor attention were identified as Factor 2, and Factor 3, was 
categorized as difficulty with attention (Llorente et al., 2009). 
 The CCTT has been used in published studies on South African children and 
adolescents. In a study by Ferrett et al (2010), researchers used the CCTT as part of their 
neuropsychological battery to assess the cognitive functioning of adolescents (13-15 years) 
with an alcohol use disorder. Another South African study on paediatric HIV utilised the 
CCTT in its cognitive test battery (Hoare et al., 2016).  
The Children’s Memory Scale (CMS). The CMS includes eight tests designed to 
primarily measure learning and memory among children aged 5 to 16 years (Cohen, 1997). 
The Numbers subtest consists of two components: Numbers Forwards and Numbers 
Backwards. In Numbers Forwards the examiner reads out numbers which participants are 
expected to repeat back and is used to measure attention. On the other hand, Numbers 
Backwards is used to assess working memory and, in this component, participants are 
required to repeat the order of numbers as presented by the examiner in reverse order. I only 
used the Numbers Backwards component since working memory is included in the cognitive 
flexibility domain of P. Anderson’s (2002) model of EF.   
Psychometric properties. Reliability coefficients for the Numbers subtest range from 
0.71 to 0.83. The test re-test reliability for the subtests range from 0.71 to 0.91 and the 
structure and content validity ranges from 0.06 to 0.96, across all ages. Moreover, the CMS 
has been found to correlate well with the Wechsler Memory Scale – III (WMS-III), with 
measurement indices reflecting convergent validity on similar sub-domains.  
The CMS has been used with a sample of children aged 8 -18 years for HIV research 
in USA (Nichols et al., 2012). It has also been used on a South African population for 




Delis-Kaplan Executive Function System (DKEFS).  The DKEFS comprises nine 
subtests and is designed to test executive function in children and adults from age 8 to 89 
(Delis, Kaplan & Kramer, 2001). I used two subtests from this test battery: Verbal fluency 
and the Towers subtests. Verbal fluency is included in the information processing domain of 
P. Anderson’s (2002) EF model. The Towers subtest is used as a measurement of planning 
and falls under the goal setting domain of the P. Anderson’s (2002) EF model. From the 
Towers subtest I used the achievement score, move accuracy score and the rule violations 
score. 
The Verbal Fluency subtest is designed to assess processing speed, verbal retrieval 
and recall, self-monitoring and inhibition. It consists of three conditions or tasks; a phonemic 
fluency task (condition 1), semantic fluency task (condition 2), and a switching task 
(condition 3). In the phonemic fluency task participants are required to generate words 
beginning with a specified letter. Conventionally, participants are given the letters F, A, and S 
as the starting letters of the words that they need to generate. I used M, A, and T in this study 
based on previous local research (Baufeldt, 2009).  
In the semantic fluency task participants are expected to generate words within a 
specified category (animals and the names of boys or girls). Lastly in the switching task 
participants are required to switch between stimuli (furniture and fruits).  
 The Towers subtest is used to measure goal setting ability, including problem solving, 
planning abilities and strategic thinking. The test stimuli consists of a board with pegs and 5 
discs. The examiner places the discs on the pegs according to the stimulus book item being 
administered and then invites the participant to arrange the discs on the pegs according to the 
end arrangement shown in the stimulus book. The participant is expected to reproduce the 
arrangement as quickly as possible in the fewest number of moves while at the same time 
adhering to two rules. First, only one of the discs can be moved at a time and second, larger 
discs may not be placed on top of smaller ones. As the test continues each arrangement 
increases in complexity and the time given to complete an arrangement increases in length 
ranging from 30 seconds to 4 minutes.  
Psychometric properties. Test-retest coefficients are in the moderate range with great 
variability among the subtests. Internal consistency, test-retest reliability and validity have 
been established for each of the DKEFS subtests (Delis et al., 2001).  
The DKEFS test battery has been administered on a USA sample of adolescents aged 
between 9 -19 years comprising of prenatally infected HIV-positive and prenatally HIV 




been used in South African paediatric HIV research (see Hammond, Eley, Ing, Wilmshurst, 
2019).  
Paediatric Neuropsychology Developmental Questionnaire (short form version) 
(PNDQ). This is a screening questionnaire aimed at obtaining information related to 
participants’ developmental history. It incorporates questions that relate to pregnancy and 
birth to establish whether any complications were experienced at any of these stages. Other 
questions relate to schooling, to assess if there was any repeating of grades and the reasons, 
should this have occurred. There are also questions regarding the mental and medical health 
of participants aimed at establishing whether participants have been referred for mental and 
medical health reasons and also whether they were on any chronic medication. This 
questionnaire is a short form of the one used at the local paediatric neuropsychology clinic at 
the Red Cross War Memorial Children’s hospital.  
School quintile. The current study used school quintile as a proxy measurement index 
of SES and quality of education. School quintile is a South African classification for schools 
and the communities they are located in: 1 being the poorest schools and 5 the wealthiest 
schools. This classification is based on the type of community in which the school is located; 
therefore, schools that are classified in low quintiles are commonly subsidised schools in poor 
communities (Department of Basic Education, 2018).  
Viral load. I used plasma HIV viral load as a proxy for adherence, which is a method 
commonly reported in the literature (Collier et al., 2018; Margot et al., 2018; Shoko & 
Chikobvu, 2019). Participants’ viral load readings were extracted from participants’ medical 
folders at Hannan Crusaid clinic in Gugulethu.  
Procedure 
Consenting and Assenting. Given that this study formed part of the HlangananiPlus 
HCT larger study, participants in the HIV-positive group were consented by the 
HlangananiPlus HCT study team. As part of consenting to participate in the larger study 
participants were also informed of the aim, procedure, risks and benefits of the current study 
by either myself or a researcher in the study team of the larger study.  The study team of the 
larger study also presented the participants in the HIV- positive group with consent forms for 
their parents and caregivers to consider and sign, and the participants themselves were given 
assent forms before assessments began (see Appendices B and C).  
Control participants’ parents and caregivers were also given consent forms to consider 




forms to sign (see Appendices D and E). Before signing the consent/assent forms, the study 
aims, procedure, risks and benefits were explained to both participants and their parents or 
caregivers.  Explanation of the study was carried out in person and telephonically and in all 
instances an isiXhosa translator was there to assist.  
All consent, assent and testing record forms were translated into isiXhosa by the 
University of Stellenbosch Language Centre; the Language Centre also performed back 
translation on all the forms to ensure validity and authenticity of translation.   
Testing of participants. Testing of the HIV-positive group was carried out at the 
Hannan Crusaid Clinic in Gugulethu on Friday afternoons and Saturday mornings in an 
enclosed room to ensure confidentiality. Control participants were tested on Saturdays in the 
Psychology department at UCT in quiet rooms to ensure confidentiality. 
I tested participants together with a two other neuropsychology Masters students and a 
Psychology Honours student, who assisted. At each testing session there was an interpreter 
present (see Appendix N for interpreters’ details), who was experienced in the administration 
of the neurocognitive tests, to assist with translation as participants were isiXhosa first 
language speakers.  However, some participants (in both groups) were also fluent in English 
and despite the presence of an interpreter who translated all instructions in isiXhosa, elected 
to give their responses in English for some of the neurocognitive tests.  
Each testing session lasted for approximately 2 to 2.5 hours per participant including 
breaks during which participants were provided with refreshments. At the end of testing the 
control participants received R50 for transport and a R50 food voucher as compensation for 
their time. Participants in the HIV-positive group were provided with R30 for transport. The 
transport compensation money for the HIV-positive group was decided as part of the larger 
HlangananiPlus HCT project on account of the testing site being located within the 
participants’ community. The order of the tests is included in appendix F.  
Data Analysis 
Data was analysed using SPSS Version 25. Where assumptions underlying statistical 
tests were violated, the appropriate non-parametric tests were used. For the statistical 
analysis, the independent variable was the group variable and the dependent (outcome) 





For the between-subjects analyses, the executive function scores of the HIV-positive 
group were compared to that of the control group. I also ran a within-groups analysis based 
on age at initiation of ART for the group with HIV.  
Scoring of neurocognitive data. I scored all the data according to the procedures of 
the test manuals of each test.  I converted all the neuropsychological test variables into age 
appropriate scaled scores; the only exception was for the CCTT2 score which I left as a raw 
score measurement of time. 
Scaled scores are statistically adjusted raw scores based on the normative 
performance standards of different tests. Notably, scaled scores are helpful in ascertaining 
comparability or differences in group performance. Additionally, scaled scores allow for 
maintenance of consistency in score interpretation particularly when different tests have been 
utilised (Tan & Michelle, 2011).  
Main Analysis. Between-group differences on continuous demographic variables 
were mainly evaluated using independent samples t-tests. In the case of the within group 
analysis for the HIV-positive group, based on age at initiation of ART, I used a Kruskal-
Wallis H test, given the group sizes. Chi-square or Fisher’s Exact tests (when >20% of 
expected cell counts are <5) were used to examine categorical variables. Descriptive statistics 
were computed on the demographics for all participants; this included descriptors such as sex, 
age, language, school quintile and intellectual ability. 
Executive function (EF). 
Deriving and comparing composite scores. Due to the large number of dependent 
variables compared to the small sample size, a hybrid method using composite scores was 
used (see Ferrett et al. 2010). To do this, the executive function neuropsychology test battery 
was sorted into composite domains (cognitive flexibility, information processing, attentional 
control, goal setting) based on P. Anderson’s (2002) EF model, and theoretical assumptions 
and established categorizations. Individual neuropsychological test variables were converted 
to z-scores, which were categorized into composites for the four domains outlined in P. 
Anderson’s (2002) EF model and averaged to yield an overall composite EF z-score (Medina 
et al., 2007).  
I then assessed whether the EF z-scores shared enough variance to be considered one 
overarching factor. Cronbach’s Alpha for the 17 EF subtests was 0.713, indicating that the 
items sufficiently measure one construct (executive functioning). I further calculated 
Cronbach’s alpha for each EF domain: cognitive flexibility, information processing, 




information processing, 0.83, for attentional control, 0.84, and for goal setting, 0.69, 
indicating that the tests in these domains sufficiently measure the same / similar construct. 
Effect size.  To measure effect size, I used Cohen’s d. Small, medium and large effect 
sizes, are represented by values of 0.2, 0.5, and 0.8 respectively (Field, 2009). This effect size 
was useful in assessing the magnitude of the results obtained.   
Correlations. I was also interested in assessing associations between adherence for 
the HIV-positive group, measured by viral load, and executive function scores. Therefore, I 
computed correlations between the four executive function domains and adherence using 
Pearson’s r. I grouped the viral load data into three: group 1 were participants with a low 
detectable viral load and a viral load < 20 copies/ml; group 2 were participants with a viral 
load > 20 copies/ml but < 2,500 copies/ml, and group 3 were participants who had a viral 
load > 80,000 copies/ml. The groupings of viral loads were then correlated with the 
composite executive function scores. 
Missing data.  Where there was missing data, I excluded the cases pairwise. This 
means that participants with missing data were excluded, but only for specific analyses 
(Field, 2009). 
Outliers. Individual test scores that scored either above or below the mean by at least 
two standard deviations were identified as outliers and were excluded from the analyses 
(Field, 2009). I do include the results both before and after the removal of outliers though in 
order to promote transparency. Outliers are extreme values that lie far away from the 
observed distribution pattern of data points. By nature, outliers tend to introduce bias in the 
computation of test statistics resulting in either overestimated or underestimated statistical 
values (Kwak & Kim, 2017; Laurikkala et al., 2000).  
 
Ethical Considerations 
I received ethical clearance from both the University of Cape Town’s Psychology 
Department Research Ethics Committee and the Faculty of Health Sciences Human Research 
Ethics Committee (HREC) (see Appendix G & H). Regarding HREC clearance, the current 
study’s ethical provisions were incorporated into the HlangananiPlus HCT larger project’s 
overall ethical protocol. An ethical amendment to include community controls was approved 
by the University of Cape Town’s Psychology Department Research Ethics Committee. The 
control data was collected as part of an Honours research project by Bryony Dyssell, which 
was linked to, and a pilot study for, the current study (see Appendix I). I was fully involved 




 Consent, voluntary participation and confidentiality. Written consent and assent 
was obtained from parents/caregivers and participants, respectively. Participants and 
parents/caregivers were told of the voluntary nature of participating in this study and that 
there would be no negative repercussions should they opt to withdraw from the study at any 
point.  
Confidentiality and anonymity. Participants were assured of confidentiality and 
anonymity regarding all data collected. Participants’ names during data extraction and 
analysis were replaced with participant identity numbers (PIDs) to ensure anonymity. Data 
was treated confidentially and access to study records was limited to myself, my supervisor 
and co-supervisor, and those directly involved in the research. Study records were further 
kept in locked cabinets and in computers with password access codes.  
Risks, benefits and compensation.  
Risks. Participants were not exposed to physical, psychological or social risks in the 
study. However, due to extended testing sessions some participants may have become 
fatigued. Where this was observed intermittent breaks with light refreshments were held. 
 Benefits. The key benefit of the study was the valuable knowledge that was gained 
from the research regarding the impact of HIV on executive function in HIV-positive 
adolescents and also the influence of non-neurologic factors on cognitive functioning in 
healthy controls.    
Compensation. Participants in the HIV-positive group received R30 as compensation 
for transport, given that testing was carried out within their community; they also received 
refreshments during breaks. Testing of control participants took place outside of their 
communities, at UCT, therefore they received R50 towards transport as well as a R50 food 













The HIV-positive participants in the current study sample were all prenatally infected 
with HIV. Ten (10) of them were initiated on ART before age 5; five (5) started treatment on 
ARVs between age 6 – 10, and four (4) participants after age 10. The date of treatment 
inception was not included in the medical files of 3 participants. Although this was not one of 
the aims of the study, a review of the means for the three groups based on age of initiation of 
ART, showed no real variance, and a Kruskal-Wallis H test, showed no significant within-
group variance based on this variable (p .164) for age and across all composites.  
Descriptive statistics were computed for all the demographic variables for both the 
HIV-positive and Control groups to determine sample characteristics. These are outlined in 
Table 1. There were no significant between-group differences for any of the demographic 
variables (all p’s > .150). This result indicates that the sample demographic characteristics 
have not disproportionately influenced the executive function outcome variables. No statistics 
were performed for home language since all participants were isiXhosa first language 
speakers.  
 
Table 1  
Sample Demographic Statistics (N = 44) 
  HIV group  Control group Test Statistics 
 n M (SD)/ratio n M (SD)/ratio t/χ2 p ESEa 
Age (months) 22 185.13 (10.82) 22 183.55 (9.58) -0.52 .609 0.15 
Sex (F:M) 22 15:7 22 18:4 1.09 .296 0.16 
Quintileb (1-5) 21 3.00c (0.71) 22 2.68 (0.72) -1.47 .150 0.45 
Fee-paying (Y:N) 21 3:18 22 1:21 d .345 0.17 
Note. ESE – Estimate Effect Size. aESE - Cohen’s d for independent sample t-tests and Cramer’s V for chi-
square tests of contingency. bQuintile – South African public school ranking system based on the wealth of the 
surrounding community (1 being the poorest and 5 being the wealthiest) to determine learner subsidisation. Data 
was retrieved from the Department of Basic Education (DBE, 2018). cOne HIV participant did not provide name 
of their school; therefore, the sample size was reduced to n = 21. dFisher’s Exact Test performed because > 20% 
of expected cells counts < 5.  
 
General intellectual functioning 
As reflected in Table 2, there were no significant between-group differences in terms 




The mean scores VIQ, PIQ, and consequently, FSIQ, fall within the borderline range for both 
groups, however, the means for the HIV-positive group are expectedly lower than that of the 
control group.  
 
Table 2  
General intellectual ability outcomes: between-group comparisons HIV positive group vs 
controls (N = 44) 
  HIV group  Control group Test Statistics 
 n M (SD) n M (SD) t p ESEa 
PIQ 22 75.09 (13.17) 22 78.55 (14.48) 0.83 .206 0.25 
VIQ 22 72.59 (11.67) 22 75.45 (12.52) 0.79 .218 0.24 
FSIQ 22 71.50 (11.80) 22 75.23 (11.51) 1.06 .148 0.32 
Note. Means are presented with standard deviations in parentheses.  
aESE is Cohen’s d (0.2- small, 0.5- medium, 0.8- large). PIQ: Performance intelligence quotient; VIQ: Verbal 
intelligence quotient; FSIQ: Full scale intelligence quotient. 
 
 
Executive function composites 
The individual subtests that make up each of the four domains (cognitive flexibility, 
information processing, attentional control and goal setting) are shown in Appendix K. 
Before the removal of outliers. Table 3 presents the neuropsychological test 
performance of the HIV group and Control group before the removal of outliers.  There were 
no significant between-group differences in terms of the individual composite executive 















Table 3  
Executive function composites: between-group comparisons HIV group vs Controls (before 
removal of outliers) 
Note. Means are presented with standard deviations in parentheses. 
a
ESE is Cohen’s d (0.2- small, .5- medium, 
0.8- large). 
b
Cognitive flexibility: 2 participants from the HIV group did not complete the switching task 
included in the composite score for cognitive flexibility. 
c
Information processing: 1 participant from the HIV 
group did not complete the verbal fluency task included in the composite score for information processing. 
EF – Executive function. 
d
EF Total: The EF score could not be computed for 2 participants from the HIV group 
due to non-completion of tasks. 
 
Removal of outliers. Executive function composite scores > 2SD above or < 2SD 
below the mean were identified as outliers and were removed (Field, 2009). Thus, four 
adolescents from the HIV-positive group were removed listwise from the data analysis 
because they scored > 2 SD above the mean on their executive function test composites (one 
on cognitive flexibility, one on processing speed, and two on the EF total). One Control 
adolescent was removed from the data analysis because they scored > 2 SD above the mean 
on the cognitive flexibility composite.  
Table 4 presents the data of the Control and HIV-positive group after removal of the 
outliers. The results show that adolescents with HIV performed significantly worse on 
Information Processing (p = .042) with a moderate effect size of 0.55. The results further 
showed a trend for the HIV-positive group to perform worse on the total executive function 
score (p = .068), with a moderate effect size.   
 
  HIV group  Control group Test Statistics 
 n M (SD) n M (SD) t p ESEa 
Composite scores        
Cognitive Flexibilitya 20 -0.05 (0.61) 22 <.001 (0.55) 0.27 .394 0.09 
Goal Setting  22 -0.02 (0.63) 22 <.001 (0.61) 0.08 .467 0.03 
Information Processingb 21 -0.34 (0.76) 22 <.001 (0.82) 1.41 .084 0.43 
Attentional Control 22 -0.26 (0.97) 22 <.001 (0.92) 0.93 .180 0.28 




Table 4  
Executive function composites: between group comparisons HIV group vs controls (after the 
removal of outliers) 
  HIV group  Control group Test Statistics 
 n M (SD)    n     M (SD)     t      p      ESE 
Composite scores        
Cognitive Flexibility 19 -0.14 (0.49) 21   -0.07 (0.46) 0.46 .325 0.15 
Goal Setting  22 -0.02 (0.63) 22   <.001 (0.61) 0.08 .467 0.03 
Information Processing 20 -0.42 (0.69) 22    <.001 (0.82) 1.78 .042
* 
0.55 
Attentional Control 22 -0.26 (0.97) 22    <.001 (0.92) 0.93 .180 0.28 
EF Total 18 -0.22 (0.36) 22    <.001 (0.53) 1.52 .068 0.48 
Note. Means are presented with standard deviations in parentheses. ESE is Cohen’s d (0.2- small, 0.5- medium, 
0.8- large) 
 
Correlations between executive function composites and adherence 
Correlations between adherence and executive function composites were computed 
for the HIV-positive group. A log function was computed to minimise the effects of the large 
variance in the viral load data. 61% of the adolescents had low detectable viral load and viral 
loads of <20 copies/ml. Of the adolescents who had a detectable viral load, 3 participants had 
extremely high viral loads > 80,000 copies/ml. For the adolescents who had a detectable viral 
load, the median was 2454 (IQR: 140 – 146091). Viral load was not significantly correlated 
with any executive function composite variables (all ps > .068) (see Table 5). However, 
Pearson’s correlation coefficient for goal setting and viral load is medium. It is also in the 
expected direction in that a negative association between goal setting and viral load is 
indicated. An unexpected finding was a positive correlation between attentional control, 
information processing, total executive function score and viral load. The associated effect 




















VL 1.00 -.135 -.328 .074 .123 .075 
p-value  .291 .068 .371 .303 .384 
Note. Pearson’s correlation co-efficient; Small: 0.1- 0.3; Medium: 0.3 - 0.5; Large: 0.5 - 1 
 
Figure 1, below, is a visual presentation of total executive function scores and viral 
load. High scores of total executive function are not consistently associated with low viral 
load (high adherence marker). Participants with high viral loads that exceeded 80,000 
copies/ml (group 3.00) attained composite executive function scores that were proportionate 
to participants with low detectable viral loads and < 20 copies/ml (group 1). Adherent 
participants (with low viral loads) also scored poorly on executive functioning.  
 
 






This study was part of a larger study, HlangananiPlus HCT (see Appendix M for details of 
study team), run by the Desmond Tutu HIV Foundation. The goal of the HlangananiPlus 
HCT study was to facilitate the transition of HIV-positive adolescents from youth to adult 
health care services. This goal came about after the Desmond Tutu HIV Foundation realised 
that the success rate of transitioning HIV-positive adolescents into adult health care services 
was poor and led to a rise in markedly poor patterns of adherence once they reached young 
adulthood (Desmond Tutu HIV Research Foundation, 2017). Poor adherence to ART among 
HIV-positive individuals is a serious concern, because it risks the vast health benefits gained 
from the roll out of HIV therapy (Heaton et al., 2011; Hudelson & Cluver, 2015; Inzaule, 
Hamers, Kityo, Rinke De Wit, & Roura, 2016; Willen, Cuadra, Arheart, Post, & Govind, 
2017). These health benefits include a decline in the emergence of HAND as well as a 
significant decline in the manifestation of opportunistic infections and an overall increase in 
life expectancy (Nachega, Mills, & Schechter, 2010; Williams et al., 2006; Spies, Ahmed-
Leitao, Fennema-Notestine, Cherner, & Seedat, 2016; Heaton et al., 2015; Willen et al., 
2017).   
 Poor adherence to ART, if not addressed, can also typically lead to negative health 
outcomes that manifest physically and/or cognitively (Heaton et al., 2011). Given HIV’s 
partiality for frontal cortices including frontal circuitries and deep white matter, it is not 
surprising that the neuropsychological profile associated with HIV infection, would 
prominently feature executive dysfunction. I used P. Anderson's (2002) executive function 
model, which divides executive functions into four main domains (attentional control, 
processing speed, cognitive flexibility and goal setting), as the theoretical framework for this 
study, to investigate the impact of an HIV diagnosis on executive functioning in adolescents.   
The aims of the current study were twofold. The first aim was to investigate between-
group differences in executive functioning between HIV-positive adolescents and matched 
HIV-negative controls. Executive function scores were derived for each of the four domains 
depicted in P. Anderson's (2002) executive function model for each group and an overall 
executive function score was computed by averaging the scores of the individual executive 
function domain scores. The hypothesis for this aim was that the sample of HIV-positive 
adolescents would perform more poorly on executive function tests relative to the HIV-
negative control group. The second aim was to determine whether there were associations 
between adherence and outcomes on measures of executive function, again with a focus on 




negative association between adherence (lower viral load) and executive function 
performance and that this association would be significant. 
Summary of Results 
In terms of the results, there were no significant differences in demographics or 
general intellectual functioning between the study groups. Regarding aim 1, apart from 
processing speed (after the removal of outliers) there were no significant between-group 
differences in executive functioning outcomes that emerged between the two study groups. 
Related to this finding was that the scores of the executive function tests for both groups were 
lower than the normative scores of the tests, by at least 2SDs below the tests’ means.  The 
effect sizes across the executive function domains ranged from small to medium suggestive 
that the study was underpowered, and this might contribute to the lack of significant between-
group differences. There are, however, other possible reasons that one may conjecture to 
explain these findings and these reasons are elaborated on further on in this discussion.  
Regarding aim 2, the correlations between adherence and executive functioning 
outcomes did not produce any significant associations for each of the executive function 
composites. However, the correlation coefficients between cognitive flexibility and 
adherence (viral load), goal setting and adherence were negative and thus in keeping with my 
hypothesis. Across the executive function domains, the effect sizes ranged from small to 
medium. Specifically, the effect sizes for cognitive flexibility, attentional control and 
information processing were small; however, the effect size for goal setting was in the 
medium range.  
General Intellectual Functioning 
There were no significant between-group differences in general intellectual 
functioning for the HIV- positive and Control groups, and the associated effect sizes were 
small.  Although the mean differences of the groups are not significant, the finding of low 
mean scores for the HIV-positive group, at least descriptively, compared to the Control 
group, is in accordance with other studies which also found that HIV-positive adolescents 
perform poorly when compared to controls in general intellectual functioning (Cohen et al., 
2015; Hoare et al., 2016; Smith et al., 2012). 
An important result that emerged from the outcomes for this domain is that the mean 
scores of both groups were in the borderline range (see Appendix J for the qualitative 




performance for individuals from low- to middle-income country contexts when their scores 
are compared to Western normative data (Shuttleworth-Edwards et al., 2013).  
A review of general intellectual ability is important in a study on executive function 
given that previous research has noted an association between intelligence and executive 
function. Some lines of research point out that intellectual ability is partially mediated by 
executive function and that the relationship between intellectual ability and executive 
function is explained by the constructs both being predominantly sub-served anatomically by 
the prefrontal cortex (Brydges, Reid, Fox, & Anderson, 2012).   
Aim 1: To Compare Executive Functioning Outcomes on Neuropsychological Tests, of 
HIV-positive Adolescents and HIV-negative Controls   
The findings for aim 1 are inconsistent with the outcomes of several other studies 
which report that HIV-positive adolescents, when compared to HIV-negative controls, 
perform more poorly on assessments of various executive functions (Nichols et al., 2015b). 
For example, in their study, Cohen et al. (2016) found that HIV-positive children and 
adolescents performed significantly more poorly on processing speed, working memory and 
general intellectual ability outcomes; the authors attributed these findings to HIV-induced 
reductions in both white and grey matter volume. Additionally, Hoare et al. (2016) also found 
deficiencies in processing speed and cognitive flexibility among HIV-positive adolescents 
compared to matched controls. Similarly, Boivin et al. (2018) found that HIV-positive 
children when compared to their HIV-negative peers performed poorly on problem solving, 
planning, processing speed and abstraction. Collectively, these studies suggest executive 
dysfunction in HIV-positive individuals across the subdomains that make up the core 
components in Anderson's (2002) model.  
Attentional control. For the purposes of this study and based on P. Anderson’s 
(2002) EF model, I used measures of inhibition for this domain. Inconsistent with previous 
literature, this study found no between group differences in this domain with a small effect 
size. Findings from international studies show that HIV-positive adolescents’ performance is 
compromised in this domain (Koekkoek, de Sonneville, Wolfs, Licht, & Geelen, 2008; 
Nichols et al., 2015) . For example, the study by Koekkoek et al. (2008) found that Dutch 
HIV-positive children and adolescents performed significantly lower than Dutch national 
norms in a test that measured attentional control. Even though the Koekkoek et al. (2008) 
study did not have controls and only measured performance against national normative 
scores, it is comparable to the current study with regard to the participants’ age range (6 -17 




HIV-positive children exhibited difficulties with attention when compared to HIV-negative 
controls. This finding was attributed to high plasma viral load which was determined by a 
plasma viral load level that exceeded the median of the study cohort. Even though the age of 
the participants in the Ruel et al. (2012) study fall outside of the age range of the current 
study, that study context also being SSA, suggests contextual comparisons with the current 
study.  
Cognitive flexibility. For the purposes of this study and, based on P. Anderson’s 
(2002) EF model, I used measures of working memory and switching for this domain. 
Contrary to the expectation that there would be between group differences in this domain, 
this study found none, and the effect size was negligible. According to evidence from 
international and local studies, HIV-positive adolescents exhibit difficulty on tests that 
measure mental flexibility (Cohen et al., 2015; Hoare et al., 2016; Nichols et al., 2015). For 
example, Hoare et al. (2016), using a South African sample found that HIV-positive children 
and adolescents (aged 6 - 16 years) performed more poorly in a test of cognitive flexibility 
(CCTT test) than HIV-negative matched controls. Also inconsistent with the current study, 
the investigation by Cohen et al. (2015) of a Dutch sample found that HIV-positive children 
and adolescents (8 – 18 years old) performed significantly worse on a working memory test 
than matched HIV-negative controls. Like the current study, the Cohen et al. (2015) study 
used the WISC Digit Span subtest to measure working memory and their study design also 
included healthy controls. Brain scans in Cohen et al.'s (2016) study revealed that the HIV-
positive group had smaller brain volumes than the controls evidenced specifically in reduced 
brain grey matter volumes which correlated with the observed deficits in working memory. 
Similarly, recent research by Lewis-de los Angeles et al. (2017) of HIV-positive American 
adolescents (mean age 16.7 years) also reported that HIV-related smaller brain volumes 
correlated with difficulties in working memory.   
Goal setting.  For the purposes of this study, and based on Anderson’s (2002) model, 
I used measures of planning and abstraction for this domain. There were no significant 
between-group differences found in this domain and the effect size was negligible. 
Contrastingly, some international and local studies have found that HIV-positive adolescents 
struggle with goal setting and planning (Laughton, Cornell, Boivin, & Van Rie, 2013; 
Phillips et al., 2016). Goal setting and planning are interdependent components in that goal 
setting encompasses designing strategies for the attainment of specific outcomes and is 




conceptualise sequences and integration of behaviour to accomplish a specific goal 
(Anderson, 2002; Cattie et al., 2012).  
Research by Lewis-de los Angeles et al. (2017) of 40 prenatally-infected American 
adolescents (mean age 16.7 years) and 334 HIV uninfected controls (mean age 16.1 years) 
reported planning and abstraction difficulties in the HIV group. That study attributed the 
observed planning and abstraction difficulties to HIV-related cortical thinning in frontal brain 
regions seen in brain scans of the HIV-positive group.  The difficulties with planning and 
abstraction were noted to contribute to poor decision making and risky behaviour in the HIV 
group. Impairment in planning and conceptual reasoning has also been reported in a 
longitudinal study by Boivin et al. (2018), which focussed on children aged (6 – 11 years). 
This was a multi-site study and included 611 children from South Africa, Malawi, Uganda 
and Zimbabwe. In this study there were HIV-positive children (n = 246), HIV exposed but 
uninfected (n = 183), and HIV unexposed (n = 182) children. The findings of that study 
showed that, of all the groups, the HIV-positive children performed most poorly cognitively, 
in the domains of planning and reasoning. The study attributed these executive difficulties to 
stunted growth and wasting as a developmental effect of poverty and HIV as well as to a 
pervasive late start in ART.  
In general, there is a dearth of literature on HIV-related planning deficits specific to 
adolescents.  A large body of literature focuses on adult populations (Cattie et al., 2012; 
Fujiwara, Tomlinson, Purdon, Gill, & Power, 2015; Waldrop-Valverde, Jones, Gould, 
Kumar, & Ownby, 2010). HIV-positive 
Processing speed. For the purposes of this study, and based on Anderson’s (2002) 
model, I used measures of verbal fluency and processing speed for this domain. Initially, this 
study found no significant between-group differences in this domain. However, after 
removing four participants who performed >2SD above the mean on composite EF tests from 
the sample (and were therefore, in effect, outliers), significant group differences were 
observed with a moderate effect size. Specifically, results showed that the HIV-positive 
group had a slower processing speed than the control group. This finding is consistent with a 
large body of research which has established that HIV-positive adolescents perform poorly in 
neuropsychological tests of processing speed (Boivin et al., 2018; Cohen et al., 2015; Hoare 
et al., 2016; Koekkoek et al., 2008). Koekkoek et al. (2008) found that a sample of Dutch 
HIV perinatally-infected children and adolescents between the ages of 6 – 17 performed 
below age appropriate Dutch test norms on tests of processing speed. Although this study by 




range of the participants of that study encompass the age range of the present study. A study 
by Cohen et al. (2016) of Dutch and SSA HIV-positive children and adolescents (aged 8 -18) 
found that the HIV-positive group (n = 35) performed significantly poorly when compared to 
matched healthy controls (n = 37) on tests that measured processing speed. The deficit was 
attributed to HIV-related grey matter atrophy and extensive white matter brain lesions 
identified on brain scans of the HIV-positive group. 
Processing speed is a salient HIV-related CNS feature mainly owing to a direct effect 
of the impact of the virus on brain white matter (Boivin et al., 2018; Fellows, Byrd, & 
Morgello, 2014; Koekkoek et al., 2008; Nagarajan et al., 2012; Sarma et al., 2014; Woods, 
Moore, Weber, & Grant, 2009). This is because white matter injury is predominantly 
implicated in compromised processing speed (Anderson, 2002; McArthur, Brew, & Nath, 
2005; Sarma et al., 2014). Research by Ackermann et al. (2016) found that despite early 
uptake of ART (4 months mean age), white matter changes were present in a sample of HIV-
positive children (mean age 5) especially in the cortico-spinal tracts, but with less damage 
observed in the corpus callosum. In another study by Jankiewicz et al. (2017), the authors 
also found white matter changes in a sample of children (mean age 7) despite an early uptake 
of ART. The authors hypothesize that white matter injury occurs soon after infection. Even 
though the research focused on children, its findings are relevant to this study in that they 
illustrate the vulnerability of white matter to HIV infection. Ackermann et al. (2016) however 
assert that with continuous use of ART, HIV associated white matter injury can be contained.  
In summary, the findings of the current study regarding the executive function 
domains - with the exception of processing speed (albeit only after the removal of outliers) - 
do not align with existing literature which evidences differences in scores of executive 
function tests between HIV-positive adolescents and controls (Laughton et al., 2013; Phillips 
et al., 2016).  However, the present study findings are consistent with at least some other 
studies which have similarly found no differences in cognitive functioning between HIV-
positive children and adolescents and matched controls (Blanchette, Smith, King, Fernandes-
Penney, & Read, 2002; Dollfus et al., 2010). For example, a study of Ugandan children aged 
6 to 12 years found no differences in cognitive performance of a sample of 28 prenatally-
infected children, 42 children that were prenatally exposed but HIV-negative, and 37 HIV-
negative controls. The three groups were matched for age and socioeconomic status. The 
study hypothesis was that the HIV-positive children would show more cognitive impairment 
relative to the other groups. However, their hypothesis was not confirmed in that study results 




the cognitive tests used in that study (the study used the Kaufman Battery Assessment for 
Children – K-ABC). The authors explained that these findings were likely due to the HIV-
positive children being asymptomatic due to a less aggressive disease progression. Although 
the aforementioned study is comparable to the present study in that it is also a SSA study, the 
participants’ age range is dissimilar and also all participants in that study were ART naïve 
(not yet started on ART). Further, a Dutch study of 22 HIV- positive children and adolescents 
aged between 6 – 17 years revealed that they performed within national standards on 
psychomotor tests used in that study (Koekkoek et al., 2008). It was inferred in that study that 
the result may be a function of unsuitable measures of gross motor deficits.  
Potential reasons for the non-significant between-group differences found in the 
current study are presented next. The first reason relates to reported restorative potential of 
ART on the CNS. A second consideration is with regards to social factors, which emerging 
literature reveals has profound negative implications on cognition that are separable from 
pathological mechanisms. 
Explanations for non-significant between-group differences. 
ART’s protective properties on the CNS. The positive effects of ART on the CNS are 
widely reported in literature with most researchers attributing an unprecedented decline in the 
incidence of cognitive impairment and a marked decline in AIDS-related morbidity and 
mortality, to the introduction of ART (Brahmbhatt et al., 2014; Crowell et al., 2015; Heaton 
et al., 2011; Nachega et al., 2010; Spies et al., 2016; Willen et al., 2017; Williams et al., 
2006). According to Llorente et al. (2014) ART not only protects the brain, but in some 
instances, may reverse HIV-related diseases in children. The benefits of ART are believed to 
stem fundamentally from ART’s inherent predisposition to prevent viral replication, thus 
preserving the CNS from further HIV-associated impairment (Nichols et al., 2016). It is 
therefore plausible that the finding of non-significant between-group differences in the HIV-
positive group and control group on neuropsychological test scores found in this study, reflect 
these mitigating effects of ART on the CNS. The result that 61% of the HIV-positive 
participants of this study had a low detectable viral load at the time of testing, is indicative of 
predominantly adherent patterns to ART in the HIV-positive group.  
Notwithstanding the widely reported benefits of ART on cognition, it is also 
important to acknowledge an existing body of literature that counters this view and suggests 
that while taking up ART expands life expectancy, it does not always translate to positive 
effects on cognition (Heaton et al., 2011; Louthrenoo, Oberdorfer, & Sirisanthana, 2014; 




not correspond to improvements in cognition even in children who had attained viral 
suppression (Puthanakit et al., 2010). Likewise, a local study by Hoare et al. (2016) of HIV-
negative children and adolescents (n = 34) and HIV-positive children and adolescents (n = 
86) aged 6 – 16 years found that despite being stably on ART, 45% of the HIV-positive 
children and adolescents had neurocognitive impairment and 18 adolescents in the HIV-
positive group met the criteria for HIVE.  
Notwithstanding inconsistent reports on the effectiveness of ART in reducing HIV-
related morbidity and cognitive deficits, the bulk of the literature in this area, however, 
conveys convincing assertions in both international and local studies on the advantages of 
ART on the CNS.  Still, emerging research is recognizing the role of environmental factors 
on cognition in the context of HIV and that these factors may confound an HIV presentation; 
one of these factors is social trauma.  
Social trauma. Although there is a wide body of research on the impact of contextual 
factors on neurocognitive development, research focussing specifically on personal adverse 
experiences is gaining traction, particularly regarding the power of such experiences to 
undermine neurocognition and confound HIV-related neurocognitive effects. Specifically, 
there is increased acknowledgement in literature of the impact of childhood trauma on 
cognition and also how childhood trauma contributes to increased HIV risk behaviour and 
infection (Clark et al., 2012; Durevall & Lindskog, 2015; Fang, Chuang, & Lee, 2016; Senn, 
Carey, & Vanable, 2008).  
An example of a study that highlights the detrimental impact of social trauma on the 
brain in the context of HIV and the resultant effects on neurocognition was conducted by 
Spies et al. (2016). The study was conducted in Cape Town, South Africa and included a 
sample of 124 HIV-positive women (age 18 - 65 years). Although conducted exclusively on 
older women the findings of the study are relevant to this study because the requirement of 
the study was that the reported trauma should have occurred before age 18 which 
incorporates the age range of this study’s participants. Specifically, participants were 
screened for abuse and neglect. As part of the study design, the women were divided into 4 
sub-groups: HIV-positive women that had experienced trauma early in life, HIV-positive 
women with no experienced trauma in their early life, HIV-negative women who had no 
early life trauma and, HIV-negative women who had experienced trauma early in their lives. 
The findings of the study revealed that the women who were dually affected by HIV and 
early life trauma had smaller brain volumes when compared to the other sub-groups. These 




cortex (anterior cingulate cortex and amygdala) and hippocampi bilaterally. The brain 
alterations were conjectured to stem from the women’s early life trauma and that they 
correlated with compromised cognitive performance particularly with regard to processing 
speed, working memory, abstraction and language ability. Essentially, relative to all of the 
study groups, the HIV-positive group with trauma performed the worst across the 
neurocognitive domains. Interestingly, the HIV-positive group with trauma performed 
comparatively to the HIV-negative group with trauma on attention, working memory and 
motor skills. Another notable finding of this study was that the HIV-positive group with no 
trauma performed similarly to the HIV-negative groups. In sum, it was only the addition of 
trauma that created a significant difference between the HIV-positive and HIV-negative 
groups on neurocognitive outcomes, with the HIV-positive groups with trauma performing 
the worst. These findings do perhaps question the role of trauma (or unaccounted for role in 
many cases) in studies that have reported significant differences in neurocognitive outcomes 
between HIV-positive and HIV-negative groups. Of course, social trauma was not assessed in 
the current study, so I cannot confidently comment on its effect relative to the current study 
results, but it does seem to be an emerging factor that should be considered in HIV research 
and may explain instances where non-significant between-group differences are found for 
HIV-positive and HIV-negative individuals.   
Overall low executive function outcome scores for the two groups. As mentioned 
already, the executive function outcome scores of both the HIV-positive group and controls 
when compared to the normative scores of the tests used were low (by at least 2 SDs below 
the tests’ means). These low scores suggest the presence of latent factors which influence 
cognition more generally, in the overall sample. Previous investigations into the impact of 
social factors on cognition reveal it to be not only profound but commonly negative (Boyede, 
Lesi, Ezeaka, & Umeh, 2013).  Moreover, the negative effect of social factors on cognition 
has been found to present similarly, clinically, to fallout from pathological or neurological 
mechanisms (Fang et al., 2016, Natrass et al., 2012; Senn et al., 2008). Although social 
factors are wide-ranging (e.g., trauma, stigmatisation, food security, employment and 
education status) in this discussion I will focus on SES and quality of education.  
Socioeconomic status (SES) and quality of education. SES is widely recognized in 
literature to impact negatively on cognitive development. So significant is the impact of SES 
on cognition that it often is demonstrable even in the absence of neurological impairment 
(Hackman, Gallop, Evans, & Farah, 2015; Jednoróg et al., 2012). Generally, a higher SES is 




limited education, malnutrition, poor medical access and poor mental stimulation, and is 
usually associated with poor cognitive functioning (Ferrett et al., 2014; Hackman et al., 2015; 
Hoare et al., 2016; Mosdell, Balchin, & Ameen, 2010). For instance, a study by Smith et al. 
(2013) in which they compared 3 groups of HIV-positive children and adolescents (7 -16 
years) with a previous HIV disease, without a previous HIV disease, and prenatally-exposed 
but not infected, found that SES appeared to sub-serve differences in performance. In that 
study, whilst all 3 groups performed in the low average range cognitively, the children and 
adolescents who lived with their parents and were from families with higher income levels 
performed better on cognitive testing.  
A related factor to SES is quality of education. Specifically, poor neuropsychological 
test outcomes have been shown to correlate with poor quality of education (Ferrett et al., 
2014; Mosdell et al., 2010; Shuttleworth-Edwards et al., 2004; Shuttleworth-Edwards et al., 
2013). Despite the collapse of the apartheid system of governance in South Africa, which 
apportioned resources according to race, disparities in resource allocation within the 
education sector have persisted well beyond the end of the apartheid regime (Ferrett et al., 
2014; Mosdell et al., 2010). These disparities have repercussions on the quality of education 
offered in schools. Poor quality of education is typically associated with schools that are 
poorly resourced - in terms of both school supplies and personnel (e.g., lower qualified 
educators). Schools with high teacher/student ratios and those geographically located in areas 
where there are higher levels of crime tend to be associated with poor quality of education 
(Ferrett et al., 2014). 
Consistent with this viewpoint, a study by Shuttleworth-Edwards et al. (2013) of 
South African learners from the Eastern Cape province (aged 12 – 13; N = 69) found that 
learners from advantaged schools outperformed learners from disadvantaged schools on 
cognitive testing by more than 10 scaled points. In that study, private and former Model C 
schools (which are predominantly English medium schools) were identified as advantaged 
schools and were associated with good quality of education. Disadvantaged schools which 
denoted poor quality of education were schools located in the townships; these schools were 
largely associated with under qualified teachers and a general lack of supplies and basic 
classroom resources such as school furniture. Using the WISC-IV, that study found that 
learners from advantaged schools fared superiorly to their peers from disadvantaged schools. 
For example, advantaged Black isiXhosa learners attained a mean FSIQ = 93.92 (SD = 5.85) 
compared to disadvantaged learners of the same race and age who attained a mean FSIQ = 




exclusion criterion the study concluded that the key explanation for the vast discrepancy in 
performance were differences in quality of education. Consistent outcomes have been 
reported in previous studies of a similar nature (Shuttleworth-Jordan & Bode, 1995; Zindi, 
2004). 
 Given that the participants in this study were predominantly from schools pegged at a 
low school quintile (i.e., school quintile 2), one may surmise that the participants came 
largely from poorly resourced schools which, as explained, are typically associated with poor 
quality of education. Given the reported relationship between neuropsychological test 
performance and poorer quality of education (Shuttleworth-Edwards et al., 2013), when 
considering the poor performance in the executive function tests of this study’s participants, it 
is possible that the low executive function scores for both groups reflect the negative effects 
of these factors on neurocognitive development reported frequently in literature (Ferrett et al., 
2014; Hackman et al., 2015; Hoare et al., 2016; Mosdell et al., 2010). It is therefore 
reasonable to contemplate that SES and poor quality of education may have had far more 
reaching implications for test performance on both groups and may have unduly hampered 
the performance of the participants. Related to SES, are methodological factors; research 
shows that using tests normed on Western populations in local contexts undermines their 
efficacy. 
Methodological factors. In discussing the role of methodological factors in the 
attainment of low executive function scores for both groups, I will focus on the impact of 
non-local neuropsychological tests on performance. 
One of the major critiques of the use of non-local neuropsychological tests in local 
settings is their apparent ineptitude in definitively discriminating performance from 
neurologically impaired and unimpaired individuals (Ferrett et al., 2014; Mosdell et al., 
2010). Typically, when using these tests in local contexts, both impaired and unimpaired 
individuals can frequently be diagnosed as being impaired (Ferrett et al, 2014; Mosdell et al., 
2010).  The apparent failure of non-local neuropsychological tests to discriminate between 
neurologically and non-neurologically intact individuals, is because non-local 
neuropsychological tests are referenced on Western norms which differ markedly from those 
in developing countries (Ferrett et al., 2014). Norms are important because they are used as a 
reference against which an individual’s performance is assessed and usually correspond to the 
contexts in which they are developed.  The tests’ norms used in this study are largely based 
on European and United States populations where the context is starkly different from South 




Furthermore, non-local neuropsychological tests appear to be more effective when 
administered on populations that have embraced a Western culture because Western 
acculturation parallels Western normative data (Ferrett et al, 2014; Manly, 2008; Mosdell et 
al., 2010).  Secondly, a higher degree of Western acculturation is assumed to espouse better 
English language proficiency and quality of education both of which advantage one who is 
tested using non-local neuropsychological tests (Ferrett et al., 2014). Given that the 
participants in this study were not first language, English speakers and that they came from a 
predominantly non-western culture, it is possible that their attaining low executive function 
scores illustrates their limited western acculturation which may have unduly affected test 
performance resulting in lower scores than expected. 
In sum, even though there was an isiXhosa translator present throughout testing, the 
influence of using tests that were designed and normed for western cultures on a 
predominantly non-western population may have impacted negatively on all of the current 
study participants’ performance.  It is possible that by using non-local tests the executive 
function scores of participants in this study may have been underestimated and therefore they 
may appear worse than they actually are (Shuttleworth-Jordan, 1996; Ferrett at al., 2014; 
Mosdell et al., 2010).  
Aim 2: To Investigate Correlations Between Adherence and Executive Function 
There is general consensus in literature that consistent adherence to ART is associated 
with improved cognitive outcomes. For example, a longitudinal study of HIV prenatally -
infected children and adolescents by Crowell et al. (2015) found that ART uptake was 
positively correlated with improved neurocognitive outcomes. This finding was based on an 
analysis of two cohorts of the study – an earlier one that had poor access to ART (due to poor 
availability) and a second one which had a more consistent access to ART. A comparison of 
these cohorts revealed that children and adolescents who not only had earlier age uptake (age 
< 3) of ART, but also had regular access to ART, exhibited improved performance on 
cognitive testing for school-related tests than the cohort that had poor access to ART. The 
improvement in cognitive testing outcome was attributed to a more consistent access to ART. 
Specific to the current study findings, the observed negative relationship between both 
cognitive flexibility and goal setting, and adherence, suggests that lower viral load (higher 
adherence) was associated with better cognitive flexibility and goal setting ability, albeit not 
significantly so. This finding, at least descriptively, is consistent with literature on HIV-
related goal setting and cognitive flexibility difficulties and how poor adherence to ART may 




that the results in the current study were not significant could perhaps be explained by the 
lack of power, given the sample size. This outcome would be consistent with that reported by 
Nichols et al. (2012) of American adolescents aged 8-18 years (N = 151) who also found no 
correlation between cognitive functioning and adherence, but largely attributed this finding to 
their small sample size. Although that study is comparable to the present study regarding the 
age range, it however used pill count as a measurement of adherence.  
In discordance with my hypothesis, the correlation between adherence and attentional 
control and information processing, although also not significant, was surprisingly positive, 
suggesting that a higher viral load (poor adherence) was associated with better attentional 
control and information processing. Given the pathophysiology of HIV, particularly its 
predilection for brain white matter and the fronto-striatal pathways, this finding is surprising 
(Abbott, Rönnbäck, & Hansson, 2006; Laughton et al., 2013; Smith & Wilkins, 2015; 
Thomas et al., 2016; Woods et al., 2009). This finding also stands in contrast with previous 
literature which determined that poor adherence is negatively associated with attentional 
control and the speed at which information is processed (Fellows et al., 2014; Wood, Shah, 
Steenhoff, & Rutstein, 2009).  
It is unclear why the correlations between adherence and the executive function 
composites were not significant and why the correlations between attentional control and 
processing speed and adherence were positive, particularly since it is widely theorized in 
literature that higher adherence to ART is associated with improved neurocognition (see 
Hudelson & Cluver, 2015; Nachega et al., 2014; Peltzer & Pengpid, 2013). It may well be 
that these unexpected findings are a result of the study being underpowered, as previously 
alluded to.  
A second plausible explanation worth considering for these unexpected findings may 
relate to statistical analyses limitations pertaining to the adherence (viral load) data. To 
explain, the adherence data (viral load) for participants used in this study is archival or 
retrospective data that was collected from patient medical files at Hannan Crusaid clinic. This 
is because procedurally the Hannan Crusaid clinic in partnership with the Desmond Tutu HIV 
Foundation does not regularly measure viral load, rather, viral load is typically measured 
when participants start to exhibit symptoms of opportunistic infections (Dr. M. Atujuna, 
personal communication, October 2018). Therefore, it is likely that the varied time points in 
viral load measurement and the collection of participant neuropsychological data may have 
introduced vast variance in the data thus introducing the risk of violating the normal 




transformed by introducing a log function to reduce possible impact of variance, potential 
effects of variance in the analysis cannot be completely discounted.  
A third probable explanation for the study findings relates to cerebral spinal fluid 
(CSF) escape. CSF escape is defined as detected CSF viral load when the plasma viral load 
reflects an undetectable level by the same laboratory assay used in measuring the plasma viral 
load (Collier et al., 2018). Essentially, this suggests that an undetectable plasma HIV reading 
may at times mask a detectable CSF HIV load which implies that virologically suppressed 
individuals may have detectable CSF viral loads (Collier et al., 2018; Letendre, 2011). The 
mechanism for CSF escape is unclear, however there is postulation that it may have to do 
with the difficulty of some ARVs to effectively cross the BBB (Letendre, 2011; Spudich et 
al., 2019). As previously mentioned, the BBB forms a protective barrier around the brain that 
obstructs the passage of toxic substances into the brain parenchyma (Collier et al., 2018; 
Smith & Wilkins, 2015).  Unfortunately, in carrying out this function, the BBB may block the 
passage of some types of ARVs (Letendre, 2011; Spudich et al., 2019). When the BBB 
blocks the passage of some types of ARVs, it can effectively lead to the creation of a 
protected environment or reservoir for HIV in the brain, in which the virus continues to 
replicate without ARV drug mitigation (Letendre, 2011).  
Finally, given that the current study utilized plasma viral load readings to evaluate 
adherence it is reasonable to speculate that these do not sufficiently account for CSF viral 
load levels, which may well be discordant to the plasma readings. Importantly, this reasoning 
may partially explain the contradiction reflected in the adherence data and executive function 
composite correlation coefficients derived in the current study.  
Limitations and Recommendations 
Despite taking care to ensure that this study was methodically and conceptually 
sound, this study is not without limitations. The results should thus be considered with these 
in mind. 
Firstly, the small sample size calls for a cautious interpretation of the results.  A post 
hoc analysis revealed that given the sample size with two groups (N = 44), using an alpha 
level of .05 and a medium effect size of Cohen’s d = 0.50, a statistical power of 0.49 was 
generated. This means the study is underpowered and therefore future studies should consider 
increasing the sample size. The study sample size was impacted by unforeseen delays in the 
finalisation of amendments to the ethical protocol of the larger HlangananiPlus HCT project, 
which necessitated a delay in the commencement of the larger project. Given that this study 




larger project had repercussions on the timeline of the present study especially regarding its 
commencement. The requirement was that all testing of participants of the current study had 
to be completed before the start of the HlanagananiPlus HCT project to prevent participant 
fatigue and to ensure availability of participants for the activities and tasks of the larger 
project. I managed to test 22 HIV-positive participants prior the commencement of the larger 
study.   
A second limitation to the study is that my analyses of executive function did not 
include measures of all the sub-components of the four domains outlined in P. Anderson’s 
(2002) executive function framework on which my analyses is based (e.g., feedback 
utilisation, self-regulation, efficiency and initiative). Including measures for all the sub-
components may have produced a more comprehensive analysis. 
A third limitation to the study is that it did not sufficiently assess social factors, 
specifically personal trauma and a broader description of participants’ SES. Social factors, as 
discussed, are known to have profound impact on neurocognition to the extent that they can 
mimic neurological fallout even in the absence of pathology (Hackman et al., 2015). 
Although school quintile is an informative index to gauge SES level, it is limited in 
effectively assessing SES in the sense that it does not comprehensively represent the different 
elements of SES such as family income, family asset base and level of education of parents 
(Falagas, Zarkadoulia, Pliatsika, & Panos, 2008; Peltzer & Pengpid, 2013). Therefore, future 
studies should seek to acquire a comprehensive social profile of participants. In the current 
study, as mentioned, a demographic and asset index questionnaire was distributed for 
caregivers to complete but due to poor completion and return rates the information could not 
be utilised in this study.  
Fourthly, the study did not undertake a comprehensive behavioural assessment of the 
sample in the study which would have provided more insight into the executive presentation 
of the adolescents. This is in the sense that there are behavioural components to executive 
function that cannot be exclusively nor accurately demonstrated by pencil and paper 
cognitive tests (Reisner et al., 2009). Additionally, developmentally, adolescents appear 
disproportionately more inclined to behavioural risk taking and engaging in activities 
considered HIV risk behaviours which has implications for executive function and adherence 
(Romer et al., 2017). Although the Behavioural Rating Inventory of Executive Function 
(BRIEF) and Child Behaviour Checklist and Youth Self Report were distributed as part of the 
current study, which are instruments aimed at collecting data on the behavioural components 




rates. Accordingly, future studies ought to include comprehensive evaluations of the 
behavioural profiles of adolescents from their standpoint as well as reports from caregivers 
for a balanced perspective to gain a more holistic picture of adolescent’s cognitive 
presentation especially in their daily living. Poor return rates of this form of data is well 
documented in the literature (e.g., Land & Ross, 2014).  
A fifth limitation of the current study is the use of self-reports and not a biomarker for 
establishing an HIV diagnosis for the HIV-negative controls. Although using self-reports to 
establish HIV status is prone to inaccuracies, this method is still widely used in research (e.g., 
Kufa et al., 2018; Rohr et al., 2017; Vannable et al., 2009).   
Conclusion  
 The impact of HIV on cognition is profound, especially on a developing adolescent 
brain. Even though cognitive outcomes associated with HIV are wide-ranging, executive 
dysfunction is particularly rife among HIV-positive adolescents. Although the introduction of 
ART is reported to mitigate the effects of HIV on cognition, including executive dysfunction, 
significant differences in executive functioning between HIV-positive and HIV-negative 
adolescents are still widely reported in literature with HIV-positive adolescents performing 
more poorly than HIV-negative peers. The difference in performance is invariably attributed 
to HIV-related insult to the brain. However, emerging research suggests that these effects of 
HIV on cognition are confounded by social factors, that research does not often take into 
account, and which may explain outcomes where no significant differences are found 
between HIV-positive and HIV-negative participants. Understanding the role of these factors, 
alongside the potential mitigating effects of ARVs in explaining HIV outcomes, is important.  
Given the important role of ARVs in managing the effects of HIV, investigating factors that 
support or may undermine those effects are important. Although the findings in the current 
study did not conclusively provide evidence for the role of executive functions in adherence, 
further studies with larger samples should confirm such outcomes.   
The current study adds to a growing body of knowledge on the impact of HIV on 
adolescent executive functioning. Considering that there is a paucity of research that focusses 
specifically on this group, and an even greater dearth of literature on executive function 
outcomes specifically on this high-risk population in terms of contracting HIV, the current 
study is timely. This is in the sense that a few studies have specifically investigated executive 
functions in a controlled trial of this nature; therefore, the findings of the present study are 
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APPENDIX A  
Paediatric Neuropsychology Development Questionnaire (PNDQ)_Short Form 
 
Child’s Name: ______________________________ Date of Birth: ___________________Age: _________ 
 
PREGNANCY AND BIRTH 
Were there any complications during the pregnancy? 
 
Did you take any medicine during pregnancy? Prescribed or over the counter? 
 
Did you smoke cigarettes while you were pregnant?  If so, how many? 
 
Did you drink when you were pregnant? If so, how much? 
 
Anything else, like dagga? Any drugs? 
 
Was the birth on time? 
 
If early or late, find out why 
 
Was it a natural birth or via C-section/Caesarian?  Was labor induced? 
 
Were there any complications during the birth? 
 
Were there any early separations from you?   (when and for how long) 
 
Have there been any emotionally difficult experiences for your child? 
 
SCHOOLING 
What type of school does your child attend? (mainstream / special needs) 
 
Has your child repeated any Grades? 
 
MEDICAL / MENTAL HEALTH 
 
Has your child ever been referred to a Psychologist/Psychiatry service? 
 
Please give any details of any medical or mental health problems you, your child, or your family of origin may 
have had/have. 
 
What medication is your child currently receiving? 
 
 







APPENDIX B  
Adolescent/Caregiver Consent Form 
                     
 
 
“Retaining HIV-positive youth in care: A model for transitioning adolescents receiving 
ART from paediatric to adult care” - Aim 1 Adolescent Parent/Caregiver Consent Form 
Short title: HlangananiPlus HCT 
Introduction 
We are doing research in order to understand whether a youth programme that prepares youth 
to move from adolescent care to adult care including information around health education, 
communication and life skills, goal management, information about treatment and treatment 
adherence (commitment to taking treatment regularly) will help prepare the youth better when 
they are moved to the adult clinic. As you know, as youth get older, they will need to be moved 
to the adult clinic and will begin to receive their treatment and other health services thereon. 
We want to see if having a programme like this will help ease this process for your child as 
compared to the usual standard of care.  
What is my child being asked to do? We are asking your child to be in a research study that 
will help us find out more about whether people his/her age will benefit from such a program, 
so that when they move, they are able to come to their regular appointments, continue coming 
to the clinic and take their treatment regularly and as discussed with their doctor. We ask you 
to fully read this form or have it read to you to decide if you want your child to join the study. 
Please ask if there is anything that is not clear or if you would like more information.  
Why is my child being asked to help? We are asking you to help with this research because 
your child is between 14 and 24 years of age. One of the groups of people participating in the 
research is adolescents. 
How many people are expected to participate in the research? 120 participants will be 
included this part of the study. They will be randomly put into two groups with 60 people in 
each group. One group will participate in the program and the other will receive the standard 
(usual) care at the Hannan Crusaid clinic in Gugulethu. Your child has been assigned to the 
group that will participate in the program.  
Does my child have to take part? Not at all. You can decide that your child should not be 
included in the research. If you are unsure, you can make the decision about your child being 
in the research later by using the information included in this form and talking to our research 
staff. If you do decide that your child will take part in this research, we will ask you to sign this 
form as a sign that you understand this information and that you agree for your child to be in 




the study now by signing this form, you can still change your mind at any time and withdraw 
your child from the study. 
What will be done if my child takes part in this research study? If you agree for your child 
to participate in this study by signing this form, the interviewer will sit down with your child 
and ask him/her questions. The interviewer will begin by introducing and giving your child 
more details about the programme. Then they will ask your child questions about their 
background like school, age and gender. They will also ask your child about people he/she lives 
with at home, about his/her parents or care givers, whether they work or not. We will ask your 
child about knowledge of HIV and AIDS as well as their knowledge of treatment. This 
discussion will take roughly 30 minutes. 
Second, your child will be asked to complete some games (e.g., problem solving and memory 
games) and puzzles tests to see whether he/she needs further help when it comes to treatment 
adherence. The whole process will take about 2 hours. You can stop if you are feeling tired and 
need to take a break, at any time.  
Third, your child might be requested to take part in-depth interviews where the researcher will 
ask him/her more questions about their life history, about their parents, about their disclosure 
process. They will also ask your child about community perceptions of HIV, history of 
ARV treatment and adherence, barriers to and facilitators of treatment adherence, feelings 
around living with HIV, and their future plans.  
Fourth, your child will be asked to come for sessions every week for 17 weeks, which will be 
held every Saturday at the scout hall near the Hannan clinic. During these sessions, that is when 
our training and activities will take place.  
What if the questions upset my child? If your child feels uncomfortable answering any of 
the questions on the survey, he/ she does not have to answer. He/she will be able to stop being 
in the study at any time. Also, we have a counselor who will be working with us and if you are 
upset and need more assistance, the counselor will be there to assist you. 
Does you child get paid to be a part of this study? You will be not be paid for being in the 
study but we will pay your child’s transport of R30 every time we meet for our sessions. Your 
child will also receive a meal after the session for lunch.  
Will what my child says be kept confidential? Yes. All the information that is given to us 
will be kept confidential (private). Anonymity (your name and other details being unknown) 
and confidentiality is a high priority and every effort will be made to protect it. The information 
collected will be secured, locked and/or password-protected within the DTHC offices. To safe 
guard against any loss, the recording of your interview will be stored on a safe and secure 
online facility called shared-point that allows access of your interview to only staff members 
working on this project. A backup will be stored on only one computer that is protected by a 
password at our head offices. We will not use actual names, but instead use a number 
identification system to distinguish between participants. If the results of this research are 
published or presented, your name will not be included in the study.   
Who should I contact for further information? If you have questions about the study, you  





Who can I call for information about my child’s rights as someone who is helping with 
research?  
There is a group of doctors and researchers whose job it is to help see that research is done 
carefully and that people in the research are treated fairly and it is made as safe as possible.  
If you have any questions about these things, or if you have a complaint or complaints about 
your rights and wellbeing as a participant, please contact the Human Research Ethics 
Committee: Tel: 021 406 6492 E-mail: sumaya.ariefdien@uct.ac.za 
 
STATEMENT OF CONSENT: 
I have read the information about this study and understand the explanations of it that were 
verbally given to me. I have had my questions concerning the study answered and understand 
what will be required of my child if he/she takes part in this study. 
You voluntarily consent to allow your child to participate in this study. You hereby authorize 
the collection, use and sharing of your child’s performance and other data. By signing this 




______________________________________________             _____________________  
Signature of Person Consenting and Authorizing                           Date  
______________________________________________             _____________________  
Name of Child                                                                                Age  
___________________ ___________________ _____________________ 
Study Staff Member   Study Staff Member’s Signature  Date 
Conducting IC Discussion (print)    
 
______________________ ___________________ ___________________________ 
Witness' Name (print)  Witness' Signature       Date  
 
NOTE: This form with the original signatures MUST be retained on file by the principal 
investigator.  A copy must be given to the participant.  A copy should be placed in the 






APPENDIX C  
Adolescent Assent Form 
                     
 
“Retaining HIV-positive youth in care: A model for transitioning adolescents receiving 
ART from paediatric to adult care” - Aim 1 Adolescent Assent Form 
Short title: HlangananiPlus HCT 
Note to research staff: Only adolescents who have provided you with a written parent or 
caregiver consent form can participate in the assent process. Parent or caregiver signatures 
should appear on the parent consent form. 
Introduction 
We are doing research in order to understand whether a youth programme that prepares youth 
to move from adolescent care to adult care including information around health education, 
communication and life skills, goal management, information about treatment and treatment 
adherence (commitment to taking treatment regularly) will help prepare the youth better when 
they are moved to the adult clinic. As you know, as youth get older, they will need to be moved 
to the adult clinic and will begin to receive their treatment and other health services thereon. 
We want to see if having a programme like this will help ease this process.  
What am I being asked to do? We are asking you to be in a research study that will help us 
find out more about whether people your age will benefit from such a program so that when 
they move, they are able to come to their regular appointments, continue coming to the clinic 
and take their treatment regularly and as discussed with their doctor. We ask you to fully read 
this form or have it read to you to decide if you want to join the study. Please ask if there is 
anything that is not clear or if you would like more information.  
Why am I being asked to help? We are asking you to help with this research because you 
are between 14 and 24 years of age. One of the groups of people participating in the research 
is adolescents. 
How many people are expected to participate in the research? 120 participants will be 
included this part of the study. They will be randomly put into two groups with 60 people in 
each group. One group will participate in the program, and the other will receive the standard 
(usual) care at the Hannan Crusaid clinic in Gugulethu. You have been assigned to the group 
that will participate in the program.  
Do I have to take part? Not at all. You can decide to not to be included in the research. If 
you are unsure, you can make the decision about being in the research by using the 
information included in this form and talking to our research staff. If you do decide to be in 




and that you agree to be in the research. You will get a copy of the form to keep. Even if you 
agree to be in the study now by signing this form, you can still change your mind at any time 
and withdraw from the study. 
What will be done if you take part in this research study? If you agree to participate in 
this study by signing this form, the interviewer will sit down with you and ask you questions. 
The interviewer will begin by introducing and giving you more details about the programme. 
Then they will ask you questions about your background like school, age and gender. They 
will also ask you about people you live with at home, about your parents or your care givers, 
whether they work or not. We will ask you about knowledge of HIV and AIDS as well as 
your knowledge of treatment. This discussion will take roughly 30 minutes. 
Second, you will be asked to complete some games (e.g., problem solving and memory games) 
and puzzles, tests to see whether you need further help when it comes to treatment adherence. 
The whole process will take about 2 hours. You can stop if you are feeling tired and need to 
take a break, at any time.  
Third, you might be requested to take part in-depth interviews where the researcher will ask 
you more questions about your life history, about your parents, about your disclosure process. 
They will also ask you about community perceptions of HIV, history of ARV treatment 
and adherence, barriers to and facilitators of treatment adherence, feelings around living with 
HIV, and your future plans.  
Fourth, you will be asked to come for sessions every week, for 17 weeks, which will be held 
every Saturday at the scout hall near the Hannan clinic. During these sessions, that is when our 
training and activities will take place.  
What if the questions upset me? If you feel uncomfortable answering any of the questions on 
the survey, you will still be able to stop being in the study at any time. Also, we have a counselor 
who will be working with us and if you are upset and need more assistance, the counselor will 
be there to assist you. 
Do I get paid to be a part of this study? You will be not be paid for being in the study but we 
will pay your transport of R30 every time we meet for our sessions. You will also receive a 
meal after the session for lunch.  
Will what I say be kept confidential? Yes. All the information that is given to us will be kept 
confidential (private). Anonymity (your name and other details being unknown) and 
confidentiality is a high priority and every effort will be made to protect it. The information 
collected will be secured, locked and/or password-protected within the DTHC offices. To safe 
guard against any loss, the recording of your interview will be stored on a safe and secure 
online facility called shared-point that allows access of your interview to only staff members 
working on this project. A backup will be stored on only one computer that is protected by a 
password at our head offices. We will not use actual names, but instead use a number 
identification system to distinguish between participants. If the results of this research are 
published or presented, your name will not be included in the study.   
Who should I contact for further information? If you have questions about the study, you 




Who can I call for information about my rights as someone who is helping with research?  
There is a group of doctors and researchers whose job it is to help see that research is done 
carefully and that people in the research are treated fairly and it is made as safe as possible.  If 
you have any questions about these things, or if you have a complaint or complaints about your 
rights and wellbeing as a research participant, please contact the Human Research Ethics 
Committee: Tel: 021 406 6492 E-mail: sumaya.ariefdien@uct.ac.za 
STATEMENT OF CONSENT: 
I have read the information about this study and understand the explanations of it that were 
verbally given to me. I have had my questions concerning the study answered and understand 




____________________  ____________________ _____________________ 
Volunteer’s Name (print)  Volunteer’s Signature    Date  
 
 
___________________ ___________________   _________ 
Study Staff Member    Study Staff Member’s Signature  Date 
Conducting IC Discussion (print)    
 
 
______________________ ___________________ ___________________________ 
Witness' Name (print)  Witness' Signature        Date  
 
 
NOTE: This form with the original signatures MUST be retained on file by the principal 
investigator.  A copy must be given to the participant.  A copy should be placed in the 







APPENDIX D  
Adolescent Parent/Caregiver Control Consent Form 
                     
 
 
“The executive function outcomes associated with HIV-positive adolescents in South 
Africa” - Adolescent Parent/Caregiver Control Consent Form 
Introduction 
We are doing research in order to determine whether there are significant executive function 
(e.g., thinking, planning and flexibility) differences between HIV-positive adolescents and 
HIV-negative adolescents.  
What is my child being asked to do? We are asking your child to be in a research study that 
will help us find out more about whether people his/her age differ from those who are HIV-
positive when performing a variety of cognitive tasks. We ask you to fully read this form or 
have it read to you to decide if you want your child to join the study. Please ask if there is 
anything that is not clear or if you would like more information.  
Why is my child being asked to help? We are asking your child to help with this research 
because your child is HIV-negative and between 14 and 16 years of age.  
How many people are expected to participate in the research? 60 participants will be 
included in this part of the study. One group of 30 will be HIV-positive, and the remaining 30 
will be HIV negative. Your child has been asked to be a part of the HIV negative group.  
Does my child have to take part? Not at all. You can decide that you child should not to be 
included in the research. If you are unsure, you can make the decision about your child being 
in the research by using the information included in this form and talking to our research staff. 
If you do decide that your child will take part in this research, we will ask you to sign this form 
as a sign that you understand this information and that you agree for your child to be in the 
research. You will get a copy of the form to keep. Even if you agree for your child to be in the 
study now by signing this form, you can still change your mind at any time and withdraw your 
child from the study. 
What will be done if my child takes part in this research study? If you agree for your child 
to participate in this study by signing this form, the interviewer will sit down with your child 
and ask him/her questions. The interviewer will begin by introducing and giving your child 
more details about the study. Then they will ask your child questions about their background 
like school, age and gender. They will also ask your child about people he/she lives with at 
home, about his/her parents or care givers, whether they work or not. This discussion will take 





Second, your child will be asked to complete some games (e.g., problem solving and memory 
games) and puzzles tests. The whole process will take about 2 hours. Your child can stop if 
they are feeling tired and need to take a break, at any time.  
What if the questions upset my child? If your child feels uncomfortable answering any of 
the questions on the survey, he/ she does not have to answer. He/she will be able to stop being 
in the study at any time. Also, we have a counselor who will be working with us and if your 
child or you are upset and need more assistance, the counselor will be there to assist them. 
Does your child get paid to be a part of this study? Your child will be not be paid for being 
in the study but we will pay your child’s transport of R30 on the day he/she comes in for testing 
if he/she has to travel to the testing venue. Your child will also receive a R50 meal voucher 
after testing for lunch.  
Will what my child says be kept confidential? Yes. All the information that is given to us 
will be kept confidential (private). Anonymity (your child’s name and other details being 
unknown) and confidentiality is a high priority and every effort will be made to protect it. The 
information collected will be secured, locked and/or password-protected within the Department 
of Psychology at the University of Cape Town. We will not use actual names, but instead use 
a number identification system to distinguish between participants. If the results of this research 
are published or presented, your child’s name will not be included in the study.   
Who should I contact for further information? If you have questions about the study, you  
can call the principal investigator, Bryony Dyssell, on 072 232 7862 and Vakele Gama on 
0738307778.   
 
Who can I call for information about my child’s rights as someone who is helping with 
research?  
There is a group of researchers whose job it is to help see that research is done  
carefully and that people in the research are treated fairly and it is made as safe as possible.   
If you have any questions about these things, or if you have a complaint or complaints about 
your rights and well-being as a participant, please contact the Department of Psychology 
Research Ethics Committee: Tel: 021 650 4104 
E-mail: rosalind.adams@uct.ac.za 
 
STATEMENT OF CONSENT: 
I have read the information about this study and understand the explanations of it that were 
verbally given to me. I have had my questions concerning the study answered and understand 
what will be required of my child if he/she takes part in this study. 
You voluntarily consent to allow your child to participate in this study. You hereby authorize 
the collection, use and sharing of your child’s performance and other data. By signing this 






______________________________________________             _____________________  
Signature of Person Consenting and Authorizing                           Date  
 
 
______________________________________________             _____________________  
Name of Child                                                                                Age  
 
 
___________________ ___________________ _____________________ 
Study Staff Member   Study Staff Member’s Signature  Date 
Conducting IC Discussion (print)    
 
 
______________________ ___________________ ___________________________ 
Witness' Name (print)  Witness' Signature       Date  
 
 
NOTE: This form with the original signatures MUST be retained on file by the principal 
investigator.  A copy must be given to the participant.  A copy should be placed in the 











APPENDIX E  
Adolescent Control Assent Form 
                     
 
“The executive function outcomes associated with HIV-positive adolescents in South 
Africa” - Adolescent Control Assent Form 
Note to research staff: Only adolescents who have provided you with a written parent or 
caregiver consent form can participate in the assent process. Parent or caregiver signatures 
should appear on the parent consent form. 
Introduction 
We are doing research in order to determine whether there are significant executive function 
(e.g., thinking, planning and flexibility) differences between HIV-positive adolescents and 
HIV-negative adolescents.  
What am I being asked to do? We are asking you to be in a research study that will help us 
find out more about whether people your age differ from those who are HIV-positive when 
performing a variety of cognitive tasks. We ask you to fully read this form or have it read to 
you to decide if you want to join the study. Please ask if there is anything that is not clear or if 
you would like more information.  
Why am I being asked to help? We are asking you to help with this research because you are 
HIV-negative and between 14 and 16 years of age. 
How many people are expected to participate in the research? 60 participants will be 
included in this study. One group of 30 will be HIV-positive, and the remaining 30 will be HIV 
negative. You have been asked to be a part of the HIV negative group. 
Do I have to take part? Not at all. You can decide not to be included in the research. If you 
are unsure, you can make the decision about being in the research by using the information 
included in this form and talking to our research staff. If you do decide to be in the research, 
we will ask you to sign this form as a sign that you understand this information and that you 
agree to be in the research. You will get a copy of the form to keep. Even if you agree to be in 
the study now by signing this form, you can still change your mind at any time and withdraw 
from the study. 
What will be done if you take part in this research study? If you agree to participate in this 
study by signing this form, the interviewer will sit down with you and ask you questions. The 
interviewer will begin by introducing and giving you more details about the study. Then they 
will ask you questions about your background like school, age and gender. They will also ask 
you about people you live with at home, about your parents or care givers, whether they work 




Second, you will be asked to complete some games (e.g., problem solving and memory games) 
and puzzle tests. The whole process will take about 2 hours. You can stop if you are feeling 
tired and need to take a break, at any time.  
What if the questions upset me? If you feel uncomfortable answering any of the questions on 
the survey, you will still be able to stop being in the study at any time. Also, we have a counselor 
who will be working with us and if you are upset and need more assistance, the counselor will 
be there to assist you. 
Do I get paid to be a part of this study? You will not be paid for being in the study but we 
will pay your transport of R30 on the day you come in for testing if you need to travel to the 
testing venue. You will also receive a R50 meal voucher after testing for lunch. 
Will what I say be kept confidential? Yes. All the information that is given to us will be kept 
confidential (private). Anonymity (your name and other details being unknown) and 
confidentiality is a high priority and every effort will be made to protect it. The information 
collected will be secured, locked and/or password-protected within the Department of 
Psychology at the University of Cape Town. We will not use actual names, but instead use a 
number identification system to distinguish between participants. If the results of this research 
are published or presented, your name will not be included in the study.   
Who should I contact for further information? If you have questions about the study, you  
can call the principal investigator, Bryony Dyssell, on 072 232 7862 and Vakele Gama at 
0738307778 
Who can I call for information about my rights as someone who is helping with research?  
There is a group of researchers whose job it is to help see that research is done  
carefully and that people in the research are treated fairly and it is made as safe as possible.   
If you have any questions about these things, or if you have a complaint or complaints about  
your rights and well-being as a research participant, please contact the Department of 
Psychology Research Ethics Committee: Tel: 021 650 4104,  
E-mail: rosalind.adams@uct.ac.za 
 
STATEMENT OF CONSENT: 
I have read the information about this study and understand the explanations of it that were 
verbally given to me. I have had my questions concerning the study answered and understand 











____________________  ____________________ _____________________ 




___________________  ___________________ _____________________ 
Study Staff Member   Study Staff Member’s Signature  Date 
Conducting IC Discussion (print)    
 
 
______________________ ___________________ ___________________________ 
Witness' Name (print)  Witness' Signature       Date  
 
 
NOTE: This form with the original signatures MUST be retained on file by the principal 
investigator.  A copy must be given to the participant.  A copy should be placed in the 
















6. Symbol Search 
7. CCTT 







APPENDIX G  
Ethical Clearance HlangananiPlus 
 
HEALTH IMPACT 
ASSESSMENT HEALTH RESEARCH SUB DIRECTORATE Health 
Research@westerncape.gov.za tel: +27 21 483 0866: fax: 
+27 21 483 9895 5th Floor, Norton Rose House„ 8 Riebeek 
Street, Cape Town, 8001 vvwvv.capegateway_.gov .za) 
REFERENCE: WC 201711 003 ENQUIRIES: 
Dr Sabela Petros 





For attention: Dr Millicent Atujuna 
Re: Retaining HIV-positive youth in care: A model for transitioning adolescents receiving ART 
from 
paediatric to adult care: HlcngananiPlus. 
Thank you for submitting your proposal to undertake the above-mentioned study. We are 
pleased 
to inform you that the department has granted you approval for your research. 
Please contact 
following people to assist you with any further enquiries in accessing the following sites: 
Gugulethu CHC Mr Lunga Makamba 021 633 0020 
Kindly ensure that the following are adhered to: 





facilities are not interrupted. 
2. Researchers, in accessing provincial health facilities, are expressing consent to 
provide the 
department with an electronic copy of the final feedback (annexure 9) within six 
months of 
completion of research. This can be submitted to the provincial Research Co-
ordinator 
(Health.Research@westerncape.gov.za). 
3. In the event where the research project goes beyond the estimated completion date 
which was submitted, researchers are expected to complete and submit a progress report 
(Annexure 8) to the provincial Research Co-ordinator 
(Health.Research@westerncape.gov.za). 
4. The reference number above should be quoted in all future correspondence. 
Yours sincerely 
DR A HAW RIDG DIRECTOR: HEALTH IMPACT ASSESSMENT 
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APPENDIX J  
Qualitative Description of WASI Scaled Scores 
 
Qualitative Descriptions of WASI Scores 
IQ Scores Sub-test scaled score Classification 
130 and above 
120 - 129 
110 - 119 
90 – 109 
80 – 89 
70 – 79 




8 – 11 
6 – 7 
4 – 5 


















APPENDIX K TABLE 6 Neuropsychological Variables: Between-Group Comparisons 
  HIV group (n = 22)  Control group (n = 22) Test Statistics 
Variable (scaled scores) n M (SD) Median Range n M (SD) Median Range t p ESE 
Cognitive Flexibility            
Numbers Backwards 22 5.55 (2.92) 5.00 2-15 22 6.82 (3.52) 7.00 13 1.30 .100 0.39 
Switching Combined 20 4.35 (2.80) 4.00 1-12 22 5.23 (2.88) 5.00 11 1.00 .162 0.31 
Verbal Fluency: Condition 3 22 5.82 (3.20) 6.00 1-19 22 7.32 (4.26) 6.50 18 1.32 .097 0.40 
Verbal Fluency: Switching accuracy 22 3.50 (1.60) 4.00 1-9 22 3.95 (2.01) 3.50 8 0.83 .206 0.25 
Children’s Colour trails test 2 22 65.32 (44.32) 53.50 28-81 22 52.14 (13.86) 52.50 53 -1.33 .095 0.40 
Information Processing            
Coding 22 4.68 (2.19) 4.00 1-10 22 5.50 (2.22) 5.50 9 1.23 .128 0.37 
Symbol Search 22 6.82 (2.94) 7.00 1-14 22 7.77 (3.53) 7.50 13 0.98 .168 0.29 
Verbal Fluency: Condition 1 22 4.73 (3.04) 4.50 1-10 22 6.09 (2.49) 6.00 9 1.63 .055 0.49 
Verbal Fluency: Condition 2 21 6.76 (3.06) 6.00 2-16 22 7.82 (3.74) 7.00 14 1.01 .159 0.31 
Attentional Control            
Inhibition Combined 22 5.00(3.63) 5.00 1-11 22 5.64 (2.87) 6.00 10 0.65 .261 0.20 
Inhibition Total Errors 22 3.00 (2.62) 1.00 1-13 22 4.05 (3.43) 3.50 12 1.14 .131 0.34 
Goal Setting            
Similarities 22 4.23 (3.10) 3.00 1-10 22 5.23 (3.07) 5.50 9 1.08 .144 0.32 
Matrix Reasoning 22 4.95 (2.94) 5.00 1-10 22 4.36 (2.68) 4.00 9 -0.70 .245 0.21 
Tower: Achievement score 22 8.36 (2.34) 9.00 4-13 22 9.05 (2.24) 9.00 9 0.99 .165 0.30 




Tower: Rules violations ratio 22 9.00 (2.25) 10.00 1-10 22 8.86 (2.70) 10.00 9 -0.18 .428 0.06 
Towers: Move accuracy  22 7.95 (2.57) 8.00 2-11 22 7.45 (2.70) 8.00 9 -0.63 .267 0.19 
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APPENDIX N Details of Translators 
 
Name of Translator Training Formal/ 
Informal 
Previous Clinical Translation work 
Minah Koela Formal • Translator at the Red Cross War 
Memorial Hospital at the Paediatric 
Neuropsychological Clinic 
• Translator at UCT Paarl Lung and 
Health study 
Thozama Madze Formal • Translator at UCT Paarl Lung and 
Health study 
Limpho Mokoena Informal • Translator at the Red Cross War 
Memorial Hospital at the Paediatric 
Neuropsychological Clinic 
• Translator at the Groote Schuur Adult 
Neuropsychological Clinic  
 
